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ABSTRACT
Autogenous and autologous adult multipotent stromal cells are applied to treat equine
musculoskeletal injuries in clinical practice. However, options for autologous therapy in the
equine specie are restricted due to the limited biological material obtained. Induced pluripotent
stem cells represent an alternative to overcome these limitations.
Traditionally, iPSCs are produced by introducing DNA for early embryonic genes into
cells with viruses. The method evaluated, avoids the use of viral vectors and potential for
exogenous DNA integration into the cell’s genome by utilizing a lipid delivery vehicle carrying
synthetic mRNA coding for the human pluripotency factors OCT4, KLF4 and SOX2. Cells from
different tissue have specific epigenetic profiles that determine their phenotype and functionality;
hence they might have a distinct susceptibility to induction of pluripotency. We tested the
expansion capacity and potency of equine adult MSCs from adipose tissue, bone marrow, and
fibroblast following chemical transfection with synthetic mRNA of human sequences for
embryonic genes, OCT4, KLF4 and SOX2. Target gene mRNA and cell protein expression was
compared among passage (P) 3 cells from the different tissue sources before and after 7 and 14
days of transduction. Additionally, multilineage capacity and expansion rate were compared in
P10 cells. Target protein expression was higher in transduced cells at both time points compared
to untreated cells based on immunocytochemistry. Based on qRT-PCR, OCT4 and SOX2
expression was significantly higher in transfected cells after 14 days of transduction compared
untreated cells (Oct4: ASCs, P=0.030; BMSCs, P=0.005 and fibroblast, P<0.001; Sox-2: ASCs,
P=0.012; BMSCs, P=0.001 and fibroblast, P=0.005). Multilineage differentiation was detected in
transfected versus untreated cells both at passage 10 by histological staining after differentiation.

xii

Expansion rates of transduced and untreated cells were not different with the exception of
BMSCs (P<0.05). Based on these results, dedifferentiation of equine MSCs with synthetic
mRNA increases in vitro potency and expansion capacity.
The ability to induce pluripotency from MSCs obtained from multiple equine tissue
sources will significantly increase accessibility to highly characterized stem cells. This will in
turn improve the ability to predict cell behavior for customized therapies, becoming an important
model for future human applications.

xiii

CHAPTER I: INTRODUCTION
Musculoskeletal injuries result in a major economical loss for the equine industry not
only due to time away from competition but also because of the high rate of re-injury (Williams
et al., 2001; Clegg, 2012). Though the initial tendon injury often heals to some degree, the new
tissue has less functionality and greater potential to re-injury than the original (Paris and Stout,
2010). Multipotent stromal cells are an attractive alternative for clinicians to treat tendon
injuries, whether obtained from bone marrow or adipose tissue, are reported to improve tendon
repair tissue in other species (Behfar et al., 2013). However, questions about practical aspects
related to the use of this therapy are still unanswered. For instance, autologous therapy is
restricted due to limited biological material that can be harvested and there is a general lack of
characterization by immunophenotyping and trilineage differentiation before implantation.
Another concern is that cells from different tissues have distinct epigenetic profiles that can
result in phenotypically and functionally distinct cells from genetically identical precursors
(Aranda et al., 2009) and reducing the predictability of cell behavior in the patient. Differential
gene expression is not only seen in stable and discrete cells (differentiated cells) but also in
undifferentiated cells. Plus, in vitro culture expansion reduces multipotentiality and regenerative
capacity (Zhironkina et al., 2012).
Induced pluripotent stem cells represent an alternative to overcome these limitations.
Subjecting MSCs to a pluripotent inducing treatment would permit in vitro culture expansion
(Gourronc and Klingelhutz, 2012) to obtain material to treat a musculoskeletal injury. In
addition, it would permit autologous treatment with a fairly homogenous population of cells in
an injured horse. The concept of iPSc introduced by Yamanaka consists of subjecting a
differentiated cell to a gene reactivation treatment, generally by introducing genes that are
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normally expressed in early embryos (Takahashi and Yamanaka, 2006). Traditionally, iPSCs are
produced by introducing early embryonic genes into cells with recombinant DNA carried by
viruses. A limitation with use of recombinant DNA is that, unless is directed by another
technique, integration into the cell genome is non-specific and can potentially activate
endogenous oncogenic sequences. Hence, the use of recombinant DNA in these techniques has
significant limitations for clinical translation (Bayart and Cohen-Haguenauer, 2013; Okano et al.,
2013). Recently, mRNA transfection with lipofectamine was introduced as an alternative to
induce pluripotency (Warren et al., 2010). This method avoids the utilization of viral vectors and
introduction of recombinant DNA to obtain induced pluripotent stem cells. One of the goals of
this project was to determine if the tissue source of multipotent stromal cells subjected to
pluripotency induction treatment would respond differently as determined by expression of
introduced genes and allowing cell proliferation without losing multipotent characteristics. In
series of investigations, in vitro behavior including expansion capacity and multilineage
differentiation was determined in equine adult adipose, and bone marrow multipotent stromal
cells as well as adult fibroblasts before and after induction of pluripotency by introduction of
embryonic gene mRNA. There is limited information surrounding the response of adult equine
ASCs, BMSCs and fibroblasts to transfection for purposes of dedifferentiation. It is especially
important for the problem of tenogenesis to confirm improved expansion capabilities and
multilineage differentiation of treated cells from all three tissues. To date, there has been no
comparison of the induction of pluripotency of different sources of cells before utilization for
regenerative therapy by transfection of synthetic mRNA. Also, there is limited information about
the potential for induced pluripotency in equine BMSCs and ASCs for the purpose of
tenogenesis. The other goal of this study is to provide a side by side comparison of the tenogenic
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capacity of adult equine ASCs and BMSCs before and after induction of pluripotency with
synthetic mRNA. It is expected that in vitro tenogenesis will be different due to suspected high
level of mRNA of tenogenic anabolic gene (tenascin) in ASCs following tenogenic induction in
vitro compared to the other cell types prior to induction of pluripotency owing to the fact that
ASCs are present in a stromal environment similar to the one in tendons. Further, it is assumed
that cells will retain comparable expansion capacities following induction of pluripotency and
those differences in tenogenesis will be resolved by the same.
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CHAPTER II: LITERATURE REVIEW
Stem Cell Biology
Stem cells are in the focus of the biomedical research field due to their diverse use in
therapeutic applications for various disorders and trauma (Terskikh et al., 2006) specially in the
area of regenerative medicine (Brehm et al., 2012). These types of cells are appealing since they
have the ability to differentiate into diverse cell types, as well as the capacity of self-renewal,
while maintaining their characteristics. However, the number of distinct tissues they can
differentiate into and the ability to keep their properties in prolonged culture are subjected to
their previous potency state and their plasticity (Zaidi and Nixon, 2007). Hence, we have
different types of SCs that can be mainly classified according to their potency they could be
classified in totipotent, pluripotent, multipotent and unipotent cells (Spencer et al., 2011). This
potency state determines the multiplicity of tissue types a certain cell type can derive. The higher
the potency, the grater the types of tissue they can form. Plasticity is defined as the ability to give
rise to cell types different to the ones is determined by their lineage commitment (Lakshmipathy
and Verfaillie, 2005). A totipotent cell has the ultimate plasticity, since it is not committed to any
lineage and can form all the tissues in an organism; this includes the embryonic and trophoblastic
cells, which would form the embryo and part of the placenta respectively. Pluripotent cells are
characterized for being able to form all embryonic tissue types (endoderm, mesoderm and
ectoderm lineage) but lack the capacity to differentiate into trophoblast. Multipotent cells are
more committed than the latter, since they naturally can only give rise to a specific spectrum of
cell types determined by the embryological lineage they followed. Normally they are in charge
of replacing damaged cells due to physiological turnover or injury of the tissue they reside
(Bjornson et al., 1999). Thus, they are the precursors of specialized cells (Zaidi and Nixon,
2007). While the commitment into a specific lineage increases the plasticity is reduced, that is
4

why unipotent cells, also known as progenitor cells, are the least plastic and cannot self-renew.
Hence we could state that the types and number of cells into which SCs can develop are
determined by their potency state. However, there have been reports of cells being able to
transdifferentiate across lineage once they have been committed into one (Bjornson et al., 1999;
Polak and Bishop, 2006), and of cells that de-differentiate gaining a higher potency state
(Molchadsky et al., 2010; Tapia and Schöler, 2010). These phenomena are leading to ongoing
reconsiderations not only of the definitions of potency and plasticity, but also of the whole
concept of stem cell (Lakshmipathy and Verfaillie, 2005; Polak and Bishop, 2006).
SCs could also be classified based on the source as they can be isolated from embryos,
fetuses or from adult tissue (Polak and Bishop, 2006). In adult horses several reports stated that
adipose tissue (de Mattos Carvalho et al., 2009; Braun et al., 2010; Pascucci et al., 2011; Carrade
et al., 2012; Ranera et al., 2012; Burk et al., 2013; Radtke et al., 2013; Reed and Johnson, 2014),
bone marrow (Frisbie et al., 2009; Crovace et al., 2010; Lee et al., 2010; Godwin et al., 2012;
McCarthy et al., 2012; Ranera et al., 2013; Watts et al., 2013; Lange-Consiglio et al., 2013b),
peripheral blood (Marfe et al., 2012; Spaas et al., 2013a; Spaas et al., 2013b) amnion (LangeConsiglio et al., 2013a; Lange-Consiglio et al., 2013b), amniotic fluid (Sang-Bum et al., 2011),
umbilical cord tissue (Hoynowski et al., 2007; Corradetti et al., 2011), umbilical cord blood
(Koch et al., 2007; Reed and Johnson, 2008; Toupadakis et al., 2010; De Schauwer et al., 2013a;
Reed and Johnson, 2014), tendon (Stewart et al., 2009), muscle (Stewart et al., 2009; Radtke et
al., 2013), periosteum (Radtke et al., 2013), and cornea (Moriyama et al., 2013) could be used as
sources of SCs (Fig 2.1). In this case, since cells are isolated from a fully differentiated tissue
and they have the property of cells renewal plus differentiation into a specific lineage are
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Fig 2.1 Reported sites for SCs collection in the horse
classified as MSCs. Stem cells have also been isolated from equine embryos in the blastocyst
stage (Saito et al., 2002; Li et al., 2006; Guest and Allen, 2007; Guest et al., 2010) by physical or
immune dissection of the inner cell mass (Keefer et al., 2007). SCs derived from embryos are
classified as ESCs and present characteristics of SCs in a pluripotent state. Stem cells with
similar properties have been isolated from embryos in a further developmental stage when
obtained from primordial germ cells and named embryonic germ cells (Lakshmipathy and
Verfaillie, 2005). Totipotent cells are only present in the period of time from fertilization to the
initiation of embryonic divisions.
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Thus, it can be summarized that totipotent cells occur only in the first stages of embryo
development, pluripotent in later embryonic development, multipotent in late fetal and fully
developed (adult) tissue stages, and unipotent, cells in adult stages.
These classifications SCs can be separated based on whether they occur naturally or
induced. In 2006, Dr. Yamanaka was the pioneer of the technique induction of pluripotency
when he introduced exogenous genes coding for transcription factors normally expressed in
embryos, obtaining stable colonies of cells resembling those from ESCs that were called induced
pluripotent stem cells (Takahashi and Yamanaka, 2006).
A recent publication showed that an appropriate non-specific exogenous stimulus, such as
a reduction in the pH, is enough to induce changes in a fully committed cell converting them into
a pluripotent state. After this phenomenon was reported, a new term was coined: stimulustriggered acquisition of pluripotency (Obokata et al., 2014). Strong similarities were observed in
this work when the properties of the STAP stem cells were compared with ESCs. Further studies
are needed to determine if any other exogenous stimulus that are known to increase expression of
pluripotent genes, Trituration and cell membrane damage with streptomycin O are able to induce
the formation of stable STAP stem cells colonies (Obokata et al., 2014).
Embryonic Stem Cells
The first reports of derivation of ESCs in mammals were in 1981 in mice (Evans and
Kaufman, 1981; Martin, 1981). Since then, different research groups tried to replicate the
isolation in domestic species and in humans. Similar characteristics were observed between
mouse ESCs and primate ESCs (Thomson et al., 1995; Thomson et al., 1998) namely: infinite
self-renewal, differentiation into the three germ layers, teratoma formation in vivo and embryo
body formation.
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However, not all the characteristics met with mouse ESCs were demonstrated by primate
ESCs, such as incorporation into the blastocyst ICM by chimera formation or the incorporation
into the germ line was proved. These criteria were also not met with ESCs isolates in domestic
species (Keefer et al., 2007). This led to the finding that there are two types of ESCs derived
from the ICM: those derived from the early formed epiblast, derived from the ICM cells that are
not exposed to the blastocyst cavity, called naïve ESCs (also known as “truly” ESCs) and those
derived from the post-implantation epiblast, known as primed ESCs (Nichols and Smith, 2009;
De Los Angeles et al., 2012). Thus, this poses the question of whether the isolated cells in non
rodent species (Keefer et al., 2007), especially in the equine, are truly ESCs (Paris and Stout,
2010). As such, the cells are often designated as embryonic stem-like cells.
In the case of the horse, isolation of ES-like cells were performed from in vivo produced
embryos (Saito et al., 2002; Li et al., 2006; Guest and Allen, 2007; Guest et al., 2010). However,
the separation between epiblast and hypoblast (cells derived from the ICM cells that are exposed
to the blastocyst cavity) occurs around day 7 in the horse (Enders et al., 1993) when embryos are
typically recovered from the mare, showing the difficulties that are imposed in equine ESCs
research. This could explain why several groups tried to isolate and culture equine ESCs with no
published reports of successful isolation of ESCs (Paris and Stout, 2010). The limitations with
trying to use ESCs in regenerative medicine do not seem to end there.
One of the characteristics of truly ESCs is the formation of teratomas when transferred to
immunocompromised mice. However, no teratoma formation was reported when these cells that
met all the others requirements for considered them truly ESCs were transplanted in
immunocompromised mice (Li et al., 2006). Although, it is has been stated that tumor formation
by truly ESCs is more common when the host is of the same species as the derived ESCs (Erdö
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et al., 2003), no teratoma formation was observed after equine ES-like cells were transfered for
90 days into mice (Guest et al., 2010). The lack of teratoma formation observed using equine
embryonic derived stem cells might be due to a lack of potentiality properties from these ES-like
cells or maybe is a special feature of equine ESCs compared with properties reported in human
or mouse ESCs.
Immune rejection is a concern that scientist are working to remedy and this response is
hampering the advances of therapies with ESCs is a possible immune rejection from the host
after transplantation of these cells (Takahashi and Yamanaka, 2006). Only one group has tested
the immune response using equine ESCs in an homologous host (Guest et al., 2010). Although
their findings suggest that no immune reaction was induced by the transplantation of stem cells
derived from embryos, it is important to keep in mind that these cells were not probably truly
ESCs. Migration of ESCs after transplantation has been reported in other species (Srivastava et
al., 2006). Thus, this is another factor to consider when evaluating potential ESCs therapies, if
migration is unwanted in the host.
Last but not least, ethical concerns of using ESCs for regenerative therapies are always
present, because the isolation of these cells implies the destruction of a viable embryo. The
removal of the ICM from a blastocyst interrupts the formation of a new organism, depicting a
controversial fine line of when life begins (Bahadur et al., 2010). Even though ESCs present
characteristics that would make them an interesting tissue source for regenerative therapy,
certain aspects are a clear barrier for the application in the regular clinic.
Adult Multipotent Stromal Cells
The use of MSCs in regenerative therapy not only appears to be an appealing alternative
to ESCs but also it is the type of SCs that has been studied the longest. First reports of isolation
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of MSCs date to 19th century studies however the majority of the work was performed within the
last few decades (Friedenstein et al., 1968; Dominici et al., 2006; Spencer et al., 2011). However,
some aspects of MSCs are still undefined introducing a high variability between studies setting
hurdles for clinical applications and a need for uniformity (De Schauwer et al., 2011).
As mentioned before, there are different sources where MSCs can be isolated. Likewise,
they have the advantage that the isolation techniques, in most cases, are fairly simple and tested
in several species including the human (Vidal et al., 2006) and the ethical issue of destroying
embryos to obtain SCs would be avoided.
Nevertheless, the fact that diverse types of tissue are accessible for isolation of MSCs it
has been reported that cell variations between and within isolates are detectable (Giovannini et
al., 2008; Reed and Johnson, 2008).
There are different protocols of isolation (Siddappa et al., 2007) and differences in
collection are believed to be of the factors adding to the variability observed between cell
isolates (Vidal et al., 2007; Bourzac et al., 2010) turning it into an important factor to consider
when designing an applied therapy with these cells. Even SCs isolated from the blastocyst inner
cell mass may vary in developmental potential (Thomson et al., 1998), but this seems to be
worse in the case of MSCs since heterogeneity among cells within isolates increases with donor
age due to commitment toward specialization (Siddappa et al., 2007).
Another negative aspect reported, was that undifferentiated cells isolated from a given
tissue retained characteristics of the tissue of origin due to epigenetic marks, restraining cell
differentiation capability (Eilertsen et al., 2008). This is also supported by studies performed in
the horse that reported that MSCs have a tendency to differentiate into the tissue that was
harvested (Toupadakis et al., 2010; McCarthy et al., 2012). This factor known as cell
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commitment implies that in order to have a cell product with the highest potential available one
would have to isolate SCs from the same type of tissue as that tissue needing treatment, situation
that is not always feasible.
Another issue of feasibility when trying to apply MSCs in a normal clinical situation is
the difference in time between the occurrence of the lesion and the initiation of treatment (Guest
et al., 2010). However, this could be solved by cryopreservation of cells of horses that are in
sport activities and are more prone to injuries. In fact it was demonstrated that the characteristics
and functions of cryopreserved MSCs are not different from fresh (Haack-Sorensen et al., 2007).
Recent publications state that transplantation of undifferentiated cells produce trophic factors
that reduce the immune response of the host, turning the application of allogeneic cells an
alternative to autologous therapeutic treatments (Toupadakis et al., 2010; De Schauwer et al.,
2014).
Since most musculoskeletal injuries in the horse require large amounts of biological
material to repair, the expansion capacity of the MSCs is vital (Vidal et al., 2007). Not only in
vitro expansion of MSCs needs to be analyzed but also the evaluation of in vivo migration and
proliferation should be considered. Reports in the equine pointed out a different cell propensity
to division when comparing ES-like cells and MSCs (Guest et al., 2010). In an in vivo model of
an injury in the superficial digital flexor tendon side by side comparison of undifferentiated
ESCs and MSCs transplantation showed that ESCs had better survival than MSCs at all time
points examined with <5% of the MSCs injected cells surviving after 10 days (Guest et al.,
2010). They hypothesized that the lack of proliferation might be due to the inability to divide
indefinitely caused by cell senescence. These findings suggest that MSCs are not differentiating
into tenocytes and becoming part of the regenerated tissue, supporting the idea that the
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improvement in scar formation when MSCs treatment are compared with controls is due to the
recruiting of native cells by the secretion of growth and immunomodulatory factors (Burk et al.,
2013; De Schauwer et al., 2013b). It is due to determine if turning MSCs into cells that not only
modulate but that also become part of the final tissue using genetic engineering techniques,
would improve the healing process.
It appears that MSCs could be a great alternative to the ESCs for regenerative therapies
when considering immunogenicity, collection and ethical issues. However, certain features of
adult stem cells such as their limited potency, the inability to successfully expand in vitro
without reducing their multipotency characteristics, their cell origin retention and variation
between isolates make them an inconsistence and unpredictable source of cells for tissue
regeneration. In search of a treatment that might start to solve these conundrums, induction of
pluripotency qualifies as candidate since gaining cell potency and self-renewal could be achieved
with this technique.
Induced Pluripotent Stem Cells
The concept of iPSCs introduced by Yamanaka in 2006 consists of subjecting a
differentiated cell to a gene reactivation treatment, generally by introducing genes that are
normally expressed in early embryos (Takahashi and Yamanaka, 2006). This treatment changes
the potency state of the cell to one of pluripotency, closely resembling the state of ESCs. This
undifferentiated state allows for cell expansion a characteristic lost during cell differentiation.
The major goal of this technique is to establish an environment where the exogenous pluripotent
genes are expressed and lead to the activation of the endogenous counterpart. A subsequent
inactivation of the introduced genes is needed to guarantee that the cells were truly induced to
pluripotency. Of the genes evaluated that are normally expressed in early development

12

Yamanaka in 2006 narrowed down the list to only four factors needed to induce pluripotency:
OCT4, SOX2, KLF4 and c-MYC. When one of these genes from the cocktail is removed no
colonies of iPSCs are formed (removal of OCT4, SOX2 or KLF4) or their characteristics do not
resemble those observed in ESCs (removal of c-MYC) (Takahashi and Yamanaka, 2006;
Takahashi et al., 2007). The genes used for induction of pluripotency code for transcription
factors that work together to maintain ESCs in a pluripotent state. After the first reports of iPSCs
derived from mouse and humans cells, this technique was repeated only in domestic species
(including the equine specie) (Nagy et al., 2011; Khodadadi et al., 2012; Breton et al., 2013) and
those that are endangered (Ezashi et al., 2009; Shimada et al., 2010; Ben-Nun et al., 2011; Han et
al., 2011; Koh and Piedrahita, 2014) showing that these factors are part of conserved
mechanisms for pluripotency maintenance.
Pluripotency Genes
The mechanism involved in the regulation of pluripotency has not been completely
elucidated and most of the studies were performed using ESCs. It has been stated that OCT4,
SOX2 and NANOG are the core regulatory factors in ESCs (Boyer et al., 2005), however, the
addition of NANOG to the reprogramming cocktail appears to be dispensable (Takahashi et al.,
2007). The OCT4 factor also known as POU5F1(POU class 5 homeobox 1) appears to be the
more important of them since it is necessary for the activation of the other transcription factors
(Pesce and Schöler, 2001). It binds not only to 623 promotors in genes coding for diverse
proteins but also to its own regulatory region creating a positive feedback for its expression
(Boyer et al., 2005). This particular feature is needed for the reactivation of the endogenous
OCT4 gene by exogenous translated sequence, one of the objectives of the induction of
pluripotency technique. This positive feedback has been reported for SOX2 and NANOG, which
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regulate 1271 and 1687 promotors, respectively. It has been determined that these three
transcription factors interact in the regulation of 353 genes (Boyer et al., 2005). It was reported
that as embryo development progresses expression of OCT4 is restricted to the ICM without
expression in the trophoblastic cells. This regulation of the expression of OCT4 appears to be
closely orchestrated, because differential expression of this factor directs the further tissue
differentiation (Niwa et al., 2000). Expression of OCT4 has been detected in equine MSCs
derived from different tissues namely bone marrow, adipose tissue and chord tissue and blood
(Reed and Johnson, 2008; Ranera et al., 2012; Seo et al., 2013) adding more evidence to the
statement that MSCs have an intermediate state of potency between multipotency and
pluripotency gaining the ability of transdifferentiation as we discussed earlier.
One of the other agents regulating cell pluripotency and differentiation is the sex
determining region Y-box 2 gene (Avilion et al., 2003). It is detected during early embryo
development through the morula stage of mouse embryos (Niwa et al., 2000) and has a high
relevance directing tissue differentiation into the neuronal and extra-embryonic ectoderm and
gut endoderm (Avilion et al., 2003; Adachi et al., 2010). As seen with OCT4 expression,
deregulation of SOX2 leads to predominant formation of trophoblastic cells or altered lineage
differentiation (Zhao et al., 2004; Masui et al., 2007; Adachi et al., 2010).
However, one of the most important characteristics of SOX2 is the interaction with OCT4
in maintaining the pluripotency state in ESCs, because they work synergistically to activate Oct–
Sox enhancers. These enhancers increase the expression of pluripotent stem cell- specific genes,
such as NANOG, OCT4 and SOX2 itself. Using SOX2 knock out mouse models it was
determined that SOX2 is necessary for maintaining sufficient OCT4 levels in ESCs (Masui et al.,
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2007). This close interaction is such that OCT4 levels also influence the expression of SOX2
(Hattori et al., 2004).
The last member of the triad is NANOG, a homeodomain protein that directs the
propagation of undifferentiated cells (Chambers et al., 2003). The transcription factor coded by
this gene has an importance implication in the endoderm differentiation of ESCs. When the
expression of NANOG is down-regulated the pluripotent cells in the epiblast differentiate to
endodermic cells (Mitsui et al., 2003). Thus, this factor is another key component for
maintaining the pluripotent state in ESCs.
The interaction OCT4-SOX2-NANOG is a complex set of connected pathways that
control pluripotency, self-renewal, and cell fate determination (Kuroda et al., 2005; Rodda et al.,
2005; Loh et al., 2006).
Krüppel-like factor 4 and v-myc avian myelocytomatosis viral oncogene homolog are the
others factors reported by Yamanaka to be necessary for inducing pluripotency of adult somatic
cells (Takahashi and Yamanaka, 2006). These two factors are normally related with cell
proliferation and renewal and due to this properties they are normally identify in tumors, thus
frequently know as oncogenes (Huangfu et al., 2008). Genomic changes involving c-MYC such
as mutations, overexpression, rearrangement and translocation are present in different
hematopoietic tumors, including Burkitt lymphoma (Mangani et al., 2013). It is reported that cMYC not only has a great influence in gene control due to the large number of receptor sites in
the genome (Cawley et al., 2004) but also in epigenetic control. The interaction of c-MYC with
the histone acetyltransferase complex p300/CBP is suspected to be one of the reasons for the
presence of this gene in the reprogramming cocktail because it increases the ability of other
transcription factors (such as OCT4 and SOX2) to bind to their respective sites in the genome
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(Faiola et al., 2005; Takahashi and Yamanaka, 2006). The interaction between transcription
factors such as OCT4 and the recruitment of this complex for the regulation of gene expression
by epigenetic modifications has been demonstrated showing a synergic relation between c-MYC
and OCT4 (Hochedlinger and Plath, 2009). KLF-4 has also been implicated in cell cycle control
leading to potential tumor formation when this gene is altered (Ray et al., 2013). Its normal
function is apoptosis induction via the bcl-2/bax pathway, thus controlling possible tumorigenic
cells (Li et al., 2010). However, it also stimulates cell proliferation as it represses the protein p53
which is considered to be a tumor suppressor gene (Rowland et al., 2005). Apart from regulating
cell cycle, KLF4 controls the expression of SOX2 and OCT4, which also regulates NANOG
(Wei et al., 2009).
Due to the described propensity of tumorigenic formation of KLF4 and c-MYC ongoing
studies are attempting to identify chemicals to produce the epigenetic changes initiated by these
transcription factors (Huangfu et al., 2008; Lyssiotis et al., 2009; Li and Rana, 2012; Hou et al.,
2013).

The production of equine iPSCs cells without the presence of c-MYC in the

reprogramming cocktail has been reported (Khodadadi et al., 2012); therefore we used this
approach when defining our treatments in these experiments.
These findings are leading to a different approach for cellular reprogramming based
entirely on small chemical molecules. However, is due to determine if these chemical
compounds produce a broad and unspecific epigenetic editing that might lead to deleterious
effects when compared with the specific protein function carried by the introduction of
sequences coding for specific transcription factors.
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Reprogramming Techniques: Methods to Produce iPSCs
The addition of exogenous genes is traditionally performed by transduction, a viral
mediated transfection, as it relies in the intrinsic capacity of viruses to introduce genes into the
host cells. Different types of viruses have alternative strategies to induce the transcription and/or
translation of their sequences by the cell’s machinery. The most frequent type of virus used for
the induction of pluripotency technique is a lentivirus (a subtype of retrovirus), since they have
the ability to affect different types of cells regardless the stage of their cell cycle. Normally these
viruses are engineered such that they lack the information that causes pathological changes in a
cell and lead to the formation of new viral particles, and they are labeled as replication-defective
virus. Hence, these infections are considered terminal. This approach for gene delivery allowed
the development of different protocols used for induction of pluripotency as well as sufficient
iPSCs to test culture media preparation (Yamanaka, 2012). Another characteristic of this type of
virus is its ability to incorporate these sequences into the host genome, a phenomenon known as
DNA recombination. This allows the sequence not to be diluted during subsequent cell division.
However, this property that might seem, at a first glance, as an advantage posed a question in
whether this technology was going to be applied in regenerative therapy (Bayart and CohenHaguenauer, 2013; Okano et al., 2013), since most of the protocols involve a non-specific DNA
integration that could potentially activate endogenous oncogenic sequences or induced
insertional mutagenesis resulting in an altered cell cycle (Kim et al., 2008). One of the genes
normally used in this process is oncogenic, c-MYC, leading to reported tumors in derived mouse
during evaluation of quimera formation and germline transmission (Okita et al., 2007). Later
reports stated that mice derived from retroviral obtained iPSCs present this problem when the
exogenous sequence of c-MYC is not silenced (Aoi et al., 2008; Nakagawa et al., 2008;
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Yamanaka, 2012). Since the goal is to develop a source of SCs to use in regenerative therapy,
results and conclusions obtained from mouse studies should not be freely extrapolated to
expected outcomes in other species, thus alternatives to circumvent the DNA recombination
protocols must be identified. Hence, different approaches were developed to avoid the use of
recombinant DNA such as plasmids (Okita et al., 2008; Okita et al., 2011), Sendai virus (Fusaki
et al., 2009), adenovirus (Stadtfeld et al., 2008), synthesized RNAs (Warren et al., 2010),
proteins (Kim et al., 2009) and small molecules (Hou et al., 2013).
It has been reported that independent of the type of virus used for generating iPSCs,
whether if it uses a recombinant or non-recombinant strategies. Immunological response from
the host was detected when cells obtained from the same animal were transferred after the
induction of pluripotency treatment using viral particles (Zhao et al., 2011). Apparently the
inability of a complete removal of all the viral factors after obtaining iPSCs (after several
passages) with virus types that replicate constitutively like the Sendai virus are another reason
for lowering the rating of this techniques when considering cell therapy (González et al., 2011).
Previous reports of induction of pluripotency using viral vectors showed that using
specific exogenous sequences of pluripotency related genes to activate the endogenous genes can
be applied throughout a variety of species, indicating the robustness of this technique
(Yamanaka, 2012). As well as providing aid to developing a protocol without the use of feeder
cells for synthetic mRNA utilization (Warren et al., 2012).
Reports establishing a virus-free technique for obtaining iPSCs based on episomal
systems still have the problematic use of DNA that could potentially integrate into the host
genome (Miyoshi et al., 2011). Those approaches involving removable transposon like PiggyBac
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were reported to produce insertional mutations due to an integration bias for specific parts of the
genome (Davis et al., 2013).
Although the use of proteins and small molecules to induce reprogramming to
pluripotency looks promising from a future therapy perspective, the low efficiency of induction
and the difficulties of reproducible purifications and with sufficient amount for a treatment,
makes them an expensive and poorly practical technique (González et al., 2011).
Recently a ground breaking report stated that iPSCs could be obtained by subjecting cells
to stressing exogenous stimulus (Obokata et al., 2014). As we mentioned earlier this technique,
stimulus-triggered acquisition of pluripotency, still needs to be validated to determine if
unspecific gene reprogramming has the same robustness that the other pluripotency induction
techniques have.
The use of synthetic mRNA to obtain iPSCs appears to circumvent all these limitations
and may become an important tool for tissue engineering.
Synthetic mRNA Transfection
The RNA transfection system was developed to induce pluripotency without the need of
plasmids or viral vectors (González et al., 2011). It is based in the incorporation of a foreign
molecule of RNA coding for the pluripotency related factors. This molecule will then be
translated by the cell into functional proteins. In order to synthesize this molecule in vitro,
plasmids carrying a DNA copy of the gene of interest are subjected to a transcription step
performed by an RNA polymerase. The synthetic mRNA molecules obtained have to resemble
those that are normally transcribed by an eukaryotic cell in order to be processed and to avoid the
endogenous antiviral cell response to single stranded RNA, a cell mechanism conserved to
eliminate RNA virus (Warren et al., 2010; González et al., 2011). The addition of a 5’ guanine
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cap and a poly (A) tail to the transcript are required for initiation of translation. Likewise, the use
of modified bases is mandatory to escape from the intracellular immune response and the
production of type 1-inerferon genes (Angel and Yanik, 2010; Warren et al., 2010; McLenachan
et al., 2013). The stimulation of the IFN signaling primes the cells for apoptosis (McLenachan et
al., 2013) reducing cell number specially in protocols requiring multiple transfections. The
uncapped 5’end of mRNA molecule displays free triphosphates reported to be one of the agents
stimulating the immune response (Warren et al., 2010). Incorporation of modified nucleotides
bases during the RNA in vitro step synthesis substituting 5-methylcytidine for cytidine and
pseudouridine for uridine (González et al., 2011), resembling the vast posttranscriptional
modifications that endogenous mRNAs experience eukaryotic cells (Warren et al., 2010).
The delivery of mRNA into mammalian cells can be performed via electroporation or
complexing the RNA with a cationic vehicle to facilitate uptake by endocytosis (Warren et al.,
2010). In order to maintain protein expression levels of these pluripotency related factors that
could switch-on the expression of endogenous genes (Yakubov et al., 2010) a repeated treatment
needs to be performed due to the short life of the transcriptions factors and the mRNA (Warren
et al., 2010). Since a repetitive delivery of mRNA is needed, the use of a cationic vehicle such as
lipofectamine is the best approach of the two available mechanisms (Warren et al., 2010;
González et al., 2011; McLenachan et al., 2013).
The treatment protocol employed for obtaining iPSCS with synthetic mRNA was
thoroughly evaluated regarding timing, ratio and concentration of the transcripts (Warren et al.,
2010; McLenachan et al., 2013). No toxicity effect in cells treated with lipofectamine alone was
reported (Warren et al., 2010; McLenachan et al., 2013). Although most of the limitations
involved in reprogramming of adult cells are addressed by transfection with mRNA, the high
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gene dosages of the reprogramming factors resulting from direct mRNA delivery may represent
an oncogeneic risk (González et al., 2011) specially in those systems that use c-MYC, an
oncogenic factor per se. It is to determine if this protocol could be utilized for different species
and cell types.
Furthermore, the stepwise analysis of the inclusion of different factors at different time
points to further understand their relevance as well as their sequential activity is manageable with
this approach, because different mRNA cocktails could be prepared and delivered using the same
method (Warren et al., 2010). Not only for reprogramming to pluripotency but also for directing
cell differentiation in an specific manner different than one commonly used with media
supplementation, because it has been reported that differentiation of pluripotent stem cells
towards muscle cells can be induced with mRNA coding for specific myogenic factors (Warren
et al., 2010).
Reports utilizing transfection of microRNAs to induce pluripotency show the strength of
this technique (Miyoshi et al., 2011). These ribonucleotides are known regulators of gene
expression and are highly expressed in ESCs controlling pluripotency related genes (Houbaviy et
al., 2003; Miyoshi et al., 2011). Using specific miRNA alone without the transcription factors
can reprogram somatic cells to iPSC, but with a great degree of mosaicism between cells
(Miyoshi et al., 2011; Heng et al., 2013).
Potential Future for iPSCs
One of the most important reasons for investing research time and resources in
streamlining the techniques for induction of pluripotency is that they do not have the ethical
concerns of ESC. Furthermore, the possibility of developing autologous therapies and of
costumed made cells for studying a specific pathology it is appealing for tissue regeneration and
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disease modeling research areas (Kriks et al., 2011; Yamanaka, 2012). The latter seems to be a
promising field not only for the increasing number of publications in the last years but also for
the importance of developing cures for devastating maladies (Yamanaka, 2012). Patient specific
iPSCs were used to recreate the behavior of cells caused by different diseases such as
Parkinson’s, Alzheimer’s and schizophrenia (Brennand et al., 2011; Devine et al., 2011; Israel et
al., 2012; Yamanaka, 2012). Cells induced to pluripotency could also become a step in gene
editing procedures for restoring faulty genes of specific diseases (Zhu et al., 2013), setting an
important background for genetic disease in the horse like hyperkalamemic periodic paralysis,
glycogen branching enzyme deficiency and type 1 polysaccharide storage myopathy (Tryon et
al., 2009). Moreover, wild approaches like microinjecting rat iPSCs into mouse blastocysts
presenting genetic modifications for the development of such organ were also demonstrated for
developing entire organs in a heterospecific host (Kobayashi et al., 2010).
Induced pluripotent stem cells have a promising future not only in the field of
regenerative medicine. Endangered species best represents the importance of maintaining the
health and well being of any valuable specimen that should be addressed with all possible
resources and state-of-the-art treatments.

Somatic cell nuclear transfer is an important

reproductive assisted technique for the preservation of endangered animals. Since the availability
of oocytes from endangered species is scarce the need for using related species (in this case
Equus caballus) as egg donor for heterospecific cloning is necessary. Using enucleated oocytes
of a different species reduces the efficiency of SCNT due to cytoplasmic incompatibility. It has
been reported that the success rate of cloning could be improved depending on the type of cell
used as nuclear donor (Wakayama T., 2007). A pluripotent cell would reprogram to
totipotentiality with a greater efficiency than a differentiated cell during the cloning procedure.
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Moreover, cloning procedures utilizing intracytoplasmic injection of a plasmid carrying the
pluripotency genes into the oocyte prior to enucleation were reported in the horse with
statistically significant increase in blastocyst rate and higher pregnancy rates (Olivera et al.,
2013). Thus, the use of a safe technique to induce pluripotency like synthetic mRNA, would aid
in developing protocols to improve the efficiency of equine SCNT while beneficial for
endangered species such as the Przewalski's Horse (Equus ferus ssp. Przewalskii) or the Grevy's
Zebra (Equus grevyi) in an heterospecific cloning program.
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CHAPTER III:
EFFECT OF TRANSFECTION WITH SYNTHETIC MRNA IN DIFFERENT CELLS
TYPES
Introduction
Equine multipotent stromal cells are routinely applied to treat tendon lesions in clinical
practice. However, autologous therapy is unpredictable due to individual differences in cell
multipotentiality (Aranda et al., 2009). Furthermore, time is required for cell expansion prior to
clinical application. A readily available and fully characterized cell product will obviate these
limitations to cell therapy. In order to solve these issues, a pluripotency induction treatment
would be an interesting approach. It would allow the possibility of expanding cells without
losing their multipotentiality characteristics in order to have enough biological material not only
to treat a musculoskeletal injury but also to fully characterize the cells used in therapy before
applying them.
Different techniques to induce pluripotency have been reported (González et al., 2011).
However, the use of synthetic mRNA appears to be the alternative more suitable if these cells are
intended to be used in a clinical application. This is due to the fact that non recombinant DNA is
involved in this technique, avoiding the threats implied with traditional viral reprogramming
such as activation of endogenous oncogenic sequences or induction insertional mutagenesis
(Kim et al., 2009).
Delivery of mRNA into the cell can be performed via electroporation or complexing the
RNA with a cationic vehicle to facilitate uptake by endocytosis (Warren et al., 2010). The
proteins coded by the genes used to induce pluripotency have a short half life in the cells and
because no stable DNA sequence is used in this technique, a repeated transfection is needed to
supply enough transcripts until reactivation of the endogenous pluripotency sequences occurs by
self-regulation (Yakubov et al., 2010). The process required to electroporate cells implies to have
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them in suspension, adding an extra stress to the electrical stimulus that the cells are suffering: an
enzymatic treatment to detach the cells from the culture surface every time they have to be
transfected. Thus, the use of a cationic vehicle such as lipofectamine, appears to be the
alternative.
Exogenous mRNA sequences are not innocuous. Specific viruses use the strategy of
delivering their genomic material as ribonulceotides to be used by the host cell’s translational
machinery. Hence, mammalian cells have active mechanisms to face the presence of an
exogenous mRNA molecule. To avoid the immunological cell response, the synthetic mRNA
used in the pluripotency treatment needs to be modified. For that reason, modified bases were
used during the in vitro transcription process. The cytosine and uracil bases are replaced by 5methylcytidine-5’-triphosphate and pseudouridine-5’-triphosphate bases respectively, to reduce
the immune response from the treated cell.
The pluripotency genes normally used for inducing differentiated cells into a higher
potency state are OCT4, SOX2, KLF4 and c-MYC (Takahashi and Yamanaka, 2006). However,
reported changes in the expression of c-MYC are involved in tumor formation and specific
diseases (Mangani et al., 2013). Likewise, successful induction of pluripotency utilizing equine
cells was achieved without the inclusion of c-MYC in the reprogramming cocktail (Khodadadi et
al., 2012). Hence, the lipofectamine treatment was carried out only with the first three mentioned
factors.
This study was designed to provide an analysis of the response of different tissue sources
such as adult equine ASCs, BMSCs and fibroblast to an induction of treatment with synthetic
mRNA. Their ability of translating an exogenous mRNA sequence as well as the correct
localization of these proteins was assessed. The gain of a higher potency state was evaluated by
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gene expression and immunocytochemistry. The ability of maintaining their multipotency state
after a simulation of cell expansion until passage 10 was determined. Plus, their proliferation
capacity was evaluated by a cell viability assay after 21 days of culture.
Furthermore, the capability of differentiating into a clinically important tissue in the horse
such as tenogenic tissue was compared between cells types before and after treatment with the
pluripotency genes.
The information from this study will be vital for controlled clinical trials of stem cell
therapies in the horse as well as for creating a future treatment model for musculoskeletal
injuries in humans.
Materials and Methods
Cell isolation
BMSCs, ASCs and FSCs were harvested from adult horses (n=4), isolated and culture
expanded using standard procedures (see Appendix A, “Cell Collection”). Original cell isolates
were cultured to P2 in DMEM-F12 supplemented with 5% fetal bovine serum and 1% antibioticantimycotic medium (Stromal medium) with a 5000 cell/cm2 seeding density and passage at
70% confluence under standard culture conditions (5% CO2 in air, 37°C) and cryopreserved in
90% FBS with 10% DMSO and stored in cryogenic vials at -80°C.
Immunophenotype
Immunophenotyping of the isolated cells was performed before the induction to
pluripotency treatment using flow cytometry. (see Appendix A, “Flow Cytometry”). Cells were
incubated with antibodies against PE‐CD105, CD29, PE‐CD90, and CD44 for 30 minutes at
room

temperature.

A
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FITC‐conjugated goat anti‐mouse IgG for 30 minutes. For autofluorescence, control cells will
not be incubated with antibodies.
Cell morphology
Morphology of the primary cultures was assessed by immunocytochemistry using the 488
phalloidin F-Actin staining for filamentous actin to evaluate the cytoskeleton and counterstain
with Hoechst 33258 to determine nucleus location (see Appendix A, “Immunocytochemistry”).
Differentiation into specific lineages
Cell multipotentiality was determined before the induction treatment by differentiation
into the chondrogenic, osteogenic and adipogenic lineage using specific media. For adipogenic
differentiation the induction media consisting of: DMEM-Ham’s F12, 10% FBS, 33 μM biotin
(Sigma, B4639), 17 μM pantothenate (Sigma, P5155), 2μM insulin (Sigma, I5500), 1 μM
dexamethasone (Sigma, D4902), 500 μM isobutylmethylxanthine (Sigma, I5789), and 5 μM
rosiglitazone (AK Scientific, 70325). For osteogenic, cells were cultured in monolayer for 21
days in this differentiation medium: DMEM-Ham’s F12, 10%FBS, 10mM ß-glyceropospahte
(USB Corporation, 21655), 100nM dexamethasone and 0.25mM ascorbic acid 2-phosphate. The
chondrogenic differentiation media used to maintain the pellets for 21 days was DMEM high
glucose supplemented with 100nM dexamethasone, 0.25mM ascorbic acid 2-phosphate (Sigma,
A8960), 40µg/ml proline (Sigma, P0380) and 10ng/ml TGF-ß (R&D System, 243-B3).
Evaluation of the differentiation was performed with histological staining using Oil Red O,
Alcian blue and von Kossa to assess the differentiation into adipogenic, chondrogenic and
osteogenic lineages respectively. For tenogenic lineage cells in monolayer were differentiated
with a two step protocol. First, cells were incubated for 24h with stromal media supplemented
with 10ng/ml of BMP-12 (BioVision, 4572) reported to augment the formation of tendon-like
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tissue in adult multipotent stromal cells in human. Then, cells were cultured in DMEM, 15%
FBS, 0.34mM proline and 0.17mM ascorbic acid (tenogenic differentiation media) for 21 days.
Control cells were cultured in stromal media for the same period and stained as described
previously. For further details see Appendix A “Differentiation into Specific Lineages” and
“Evaluation of Trilineage Differentiation”.
Induction of pluripotency treatment
Synthetic mRNA was produced with the Ambion® mMessage mMachine® T7 kit
(Applied Biosystems, Foster City, California) using amplified samples of human DNA
sequences for OCT4, KLF4 and SOX2 using a 3:1:1 stoichiometry. Poly (A) tails were added
using the Poly(A)Tailing kit (Ambion®). The products were purified using Ambion®
MEGAClearTM kit (For further details see Appendix A, “Plasmid Preparation”, “Mini Prep
Isolation”, “Clone Selection” and “mRNA in vitro Synthesis”). The purified synthetic mRNA
for each of the three genes was bound with Lipofectamine® reagent (InvitrogenTM, Grand
Island, NY) with a total RNA of 2pmol per well of 24-well plate and was applied to P3 cell
cultures in stromal medium every day for 14 days incubated in a modular incubator containing
5% CO2, 5% O2 and 90%N2 at 38°C (see Appendix A, “Lipofectamine Transfections”).
Immunocytochemistry for pluripotency factors
Specific localization of the pluripotency related proteins was assessed with
Immunocytochemistry using the Fluorescent Human ES/iPS cell characterization kit (Milipore,
scr078) for detection of OCT4, SOX2 and NANOG expression using fluorescent microscopy
after 0, 7 and 14 days of induction (see Appendix A, “Immunocytochemistry”)
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Gene expression
Cells were trypsinized from each well and two replicates of each group were combined
(approximately 1x106 cells) into one 1.5ml tube each for each group. The cells were pelleted and
subjected to the mRNA isolation proctol using Dynabeads®mRNA DIRECT™ Kit (Ambion,
61011) following the “standard” procedure. The mRNA was eluted in 30 ul of DNAse free
water. To perform quantitative PCR all of the samples were converted to cDNA with the two
step reverse transcription kit of QIAGEN (Quantitect® Reverse transcription Kit, 205310) that
eliminates genomic DNA. Quantitative PCR was used to evaluate gene expression in the target
cells. The quantitative PCR reactions were performed with Bio-Rad SsoFast™ EvaGreen®
Supermix was used with primers from Table B.1. qRT-PCR was performed with an enzyme
activation at 95°C (1 minute) followed by 40 repeats of denature at 95°C (5 seconds) and
annealing at 60°C (30 seconds). A final denature and extension step was performed at 95°C (1
minute) and 55°C (1 minute) respectively. A melt-curve analysis was carried out by repeating 80
times and increasing 5°C every 10 seconds beginning at 55°C. Gene expression efficiency was
normalized against housekeeping genes PAP and HPRT-1 as internal controls. Quantitative data
was analyzed using the REST 2009© program. For further details see Appendix A: “RNA
Isolation”, “Conversion of mRNA into cDNA”, “Calibrator Development”, “Retro Transcriptase
Polymerase Chain Reaction”, “Purification of PCR Products” and “qRT-PCR”.
Cell proliferation assay
The capability of the cells to remain mitotically active after induction of pluripotency and
expansion until P10 was assessed using the alamarBlue® dye. The alamarBlue® assay is
quantitative with respect to time and dose as seen by the ability of metabolically active cells to
convert the reagent into a fluorescent and colorimetric indicator. First, a standard curve was
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developed to determine the time of incubation of the dye with the cells (see Appendix A, “Cell
Proliferation Assay”). The measurements for each time point were taken in three independent
replicates on days 0, 7, 14 and 21 of culture.
Statistical Analysis
Gene expression data was analyzed using the REST 2009© statistical program. The
program uses the geometric mean of multiple reference genes to normalize the results against
genes of interest since ratios are used for data evaluation; this is called the Normalization Factor.
Individual expressions are calculated relative to each reference gene and averaged using the
geometric mean. Cell proliferation assay was analyzed using the Prism 5 software using a twoway ANOVA.
Experimental Design
Experiment 1: Validation of the cells before induction of pluripotency
In order to evaluate the effect of the pluripotency treatment in different cell types, we first
determined if the cells were actual ASCs and BMSCs to compare them with fibroblast. Four
horses ranging from 2 to 10 years old that were euthanized for clinical reasons were used as
source of the tissues for the study. Multipotent stromal cells from adipose and bone marrow
targeted were isolated and characterized based on their morphological aspects, surface markers
and trilineage differentiation.
Morphology assessment
Staining with F-actin (cytoskeleton) Hoechst 33258 (nucleus) viewed with fluorescent
microscopy to determine morphological aspects in culture. Cells were seeded in a Chamber slide
at a concentration of 5000/cm2, fixed and stained with these labels.
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Immunophenotyping
The cell morphology facilitated their isolation and enrichment in the first passages but
they are not sufficient to determine their truly potency state. Expression of specific cell markers
was added to the characterization procedure of these cultured cells. The CD evaluated were:
CD105 (endoglin, type I membrane glycoprotein), CD29 (Integrin beta 1, receptor involved in
cell adhesion), CD90 (Thy-1, marker for a variety of stem cells) and CD44 (surface glycoprotein
for cell to cell interactions, cell adhesion and migration) using flow cytometry. For each
sample/antibody at least 2.0x105 cells at P2 were used. For further details see Appendix A,
“Flow Cytometry”.
Osteogenic, Adipogenic and Chondrogenic differentiation
Multipotent stromal cells have the ability to differentiate into specific cell types when
subjected to specific differentiation media. Cells used in this experiment were differentiated into
the adipogenic, chondrogenic and osteogenic lineage (see Appendix A “Differentiation into
Specific Lineages” and “Evaluation of Trilineage Differentiation”) as another assessment of their
potency state before starting the induction of pluripotency treatment.
Experiment 2: Effect of the pluripotency treatment with synthetic mRNA
The different types of cells were treated with the induction of pluripotency treatment as
described previously. Throughout the 14 days of treatment wells were evaluated each day for
colony formation. Furthermore, a sample of 4.0x104 cells treated at day 7 and 14 cells was taken
to seed the Chamber slide for immunocytochemistry. The remaining cells were used for gene
expression analysis.
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Morphology assessment: Colony formation/loss of contact inhibition
Evaluation of the treatment was determined at first under bright field microscopy
throughout the entire induction of pluripotency treatment to confirm the formation of tight
clumps of cells growing on top of each indicating loss of contact inhibition, a feature that is
presented by pluripotent cells.
Immunocytochemistry: pluripotency induction factors
To determine if the treatment with synthetic mRNA was successful qualitative
assessments of gene expression and protein localization were performed.
After 0, 7 and 14 days of induction, expression of OCT4, SOX-2 and NANOG were qualitatively
evaluated with immunocytochemistry (Fluorescent Human ES/iPS cell Characterization Kit,
Millipore, MA) using fluorescent microscopy. For further information refer to Appendix A
“Immunocytochemistry”.
Gene expression
In order to quantitatively evaluate the response of the MSCs to the pluripotency induction
treatment, expression levels of the pluripotency genes were evaluated by qRT-PCR. Because
exogenous mRNA was utilized in the treatment, an extra step during primer design was needed
to determine the specificity of the oligonucleotides used on equine sequences. Temperature
gradients were performed to set the annealing temperature when the oligonucleotides amplified
the equine sequence for the transcription factors but not the human sequence used to synthesize
the exogenous mRNA (See Appendix A, “RNA Isolation”, “Conversion of mRNA into cDNA”,
“Calibrator Development”, “Retro Transcriptase Polymerase Chain Reaction”, “Purification of
PCR Products” and “qRT-PCR”)
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Experiment 3: Evaluation of the in vitro expansion of the pluripotency induced cells
One of the goals of the induction of pluripotency treatment was to gain certain state
potency that would permit a sufficient cell expansion to obtain enough biological material to
treat an injury. Following the treatment with the pluripotency factors, cells were passaged until
they reached P10. Once proliferated, cell growth and the ability to differentiate into the
adipogenic, chondrogenic and osteogenic lineage were evaluated.
Cell growth
The capability of the cells to remain mitotically active after being proliferated was
assessed using the alamarBlue® dye. A standard curve between arbitrary fluorescence units and
a known cell number was utilized to determine the time of incubation with the dye when the
fluorescence is linear to the number of cells. The number of cells evaluated for linearity was
determined by the number of cells expected to be in a 96-well seeded at a concentration of
1000cells/cm2 after 21 days of culture. (see Appendix A, “Cell Proliferation Assay”)
Differentiation into osteogenic, chondrogenic and adipogenic lineage
Trilineage differentiation was evaluated in the same way as in experiment 1 with cells
that were induced or not induced and then expanded to P10 to simulate the cell passaging that
would had been needed to perform a clinical treatment if these cells were used. Non
differentiated controls were analyzed in the same way as the treated cells to discard artifacts due
to the technique employed
Experiment 4: Effect of pluripotency induction to the tenogenic differentiation potential of MSC
The first step of inducing the cells into a less differentiated state with the pluripotency
treatment and subsequently expanded to increase the amount of biological material produced
were evaluated. The next step is differentiating those cells into the tenogenic lineage, thus in
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future studies we can utilize this cells to compared them with undifferentiated cell
transplantation.
Evaluation of the differentiation media: Gene expression
To test the differentiation media MSCs that were collected as described in previous
experiments and differentiated into the tenogenic lineage. Expression of the tenogenesis anabolic
marker tenascin was evaluated with qRT-PCR (using the procedure as described previously)
using the three different cell types ASCs, BMSCs and fibroblast subjected to the differentiation
media (treated cells, T) and compared with cells cultured in stromal media (non-treated cells,
NT).
Effect of the pluripotency treated cells in tenogenic differentiation: Gene expression
The influence of the induction to a pluripotent state in the differentiation towards
tenogenic tissue was evaluated. The three different sources of cells were treated with the
synthetic mRNA as described previously and then subjected to the tenogenic differentiation
media (double induced cells: induced to pluripotency and later to tenogenic lineage, 2I). Controls
for each cell type were induced to pluripotency but cultured in regular media (only one
induction: induction to pluripotency, I).
Results
Experiment 1: Validation of the cells before induction of pluripotency
Morphology assessment
There was no difference observed between cell types. All cell types presented a fusiform
morphology and plastic adherence property, both typical features of isolated MSCs after culture
of the stromal vascular fraction and subjected to subsequent cell passaging (Fig 3.1 and 3.2)
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Figure 3.1 Cell morphology under conventional microscope (200x) A: ASCs B: BMSCs C:
Fibroblasts.

Figure 3.2 Cell morphology under fluorescent microscope stained with 488 phalloidin F-actin
(green) and Hoechst dye (blue) (200x) A: ASCs B: BMSCs C: Fibroblasts
Immunophenotyping
The expression of CD105, CD29, CD90 and CD44 was between the ranges normally
accepted for the characterization of human MSCs (Dominici et al., 2006). (Fig 3.3). Multipotent
stromal cells expression of CD44 was 98.6%, CD29 98%, CD105 98,7% and CD90 91.7%.
Fibroblast expression of CD44 was 91.24%, CD29 93.9%, CD105 54.6% and CD90 10.17%.
Osteogenic, Adipogenic and Chondrogenic differentiation
After differentiation cells were stained with Oil Red O, Alizarin Red and Alcian blue to
show adipogenic, chondrogenic and osteogenic characteristics respectively (Fig 3.4). All cell
isolates were able to generate the intra- (adipogenesis) or extra- (chondrogenesis and
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Figure 3.3 Immunophenotyping with CD44, CD90, CD105 and CD29 of ASCs (A, B, C and D)
and Fibroblasts (E, F, G and H) (black histogram) compared to the auto fluorescence of the cell
(green histogram)

Figure 3.4 Multipotent stromal cells after differentiation and stainedwith Oil red O (A), Alizarin
Red (B) and Alcian Blue (C)
osteogenesis) cellular products that show their capability of trilineage differentiation. Lipid
droplet formation within the cytoplasm (indicated by the red staining with the Oil Red O),
calcium deposition (indicated by the stained aggregates) and the presence of proteoglycans in the
extracellular matrix (light blue staining depicting the form of the lacunae where the nuclei are
observed due to the counterstaining with Nuclear Fast Red) indicating the adipogenic, osteogenic
and chondrogenic differentiation potential respectively.
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Experiment 2: Effect of the pluripotency treatment with synthetic mRNA
Morphology assessment: Colony formation/loss of contact inhibition
The colonies (Fig 3.5) presented characteristics similar to those found in mouse
embryonic (Keefer et al., 2007) and induced pluripotent colonies (Takahashi and Yamanaka,
2006) presenting a compact group of cells with a spherical 3D shape and a clear edge that
differentiated them from the non-clustered cells (Fig 3.6). No cell aggregates were observed in
control wells cultured over the same period of time.

Figure 3.5 ASCs (A), BMSCs (B) and fibroblast (C) colonies obtained after 14 days of
pluripotency induction treatment compared to their respective controls (D, E and F) under light
microscopy (40x)
Immunocytochemistry: pluripotency induction factors
Higher signal intensity was observed in each cell type pre- and post-induction under the
microscope with an appropriate localization of the signal, consistent with increased protein levels
of the embryonic-related proteins compared with the controls (“pre-induction”) (Fig 3.7).
Presence of these proteins was also detected on day 14 in induced cells forming colonies (Fig
3.8).
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Figure 3.6 Close caption of representative colonies at different magnification: 200x (A, B and C)
and 400x (D, E and F)

Gene expression
Significant up-regulation (P<0.05) of OCT4 and SOX2 was detected in all the cell types
compared to control cells (Fig 3.9, 3.10 and 3.11). The mean fold changes observed for OCT4
compared to the reference genes were: ASCs: 23.074, P=0.030; BMSCs: 35.448, P=0.005 and
Fibroblast: 30.95, P<0.001.

While for Sox-2 the results were:

ASCs: 230.006, P=0.012;

BMSCs: 111.071, P=0.001 and Fibroblast: 291.671, P=0.005. Although no significant changes
were detected for the expression of endogenous Klf-4 there was a tendency for up-regulation of
the transcription factor in treated BMSCs (ASCs: 1.719, P=0.175; BMSCs: 1.736, P=0.084 and
Fibroblast: 1.857, P=0.399). No statistical differences were observed between cell types.
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Figure 3.7 Immunocytochemistry of pluripotency factors after 7 days of treatment with synthetic
mRNA to induce pluripotency

Figure 3.8 Immunocytochemistry of pluripotency factors after 14 days of treatment with
synthetic mRNA to induce pluripotency
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Figure 3.9 Expression ratios of pluripotency genes in ASCs determined by qRT-PCR

Figure 3.10 Expression ratios of pluripotency genes in BMSCs determined by qRT- PCR

Figure 3.11 Expression ratios of pluripotency genes in fibroblast determined by qRT-PCR
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Experiment 3: Evaluation of the in vitro expansion of the pluripotency induced cells
Cell growth
A standard curve between arbitrary fluorescence units and a known cell number was
utilized to determine the incubation protocol with the alamarBlue® dye when the fluorescence is
linear to the number of cells (Fig 3.12A). The fluorescence was linear to number of cells after 2h
when cell numbers range from 1600-12800 with a regression coefficient of r2=0.97 (Fig 3.12 B).
No differences were observed over the time points in ASCs and fibroblast. A significant increase
proliferation of the induced BMSCs was observed at day 21 when compared to the non-induced
cells (P<0.05).

Figure 3.12(A) Standard curve between arbitrary fluorescence units and cell number (B) Linear
regression between arbitrary fluorescence units and cell number

Figure 3.13 Arbitrary Fluorescence units after incubation of alamarBlue® dye for 2h with
induced and not induced ASCs, BMSCs and fibroblast over a time period of 21 days
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Differentiation into osteogenic, chondrogenic and adipogenic lineage
There was a reduction in the response of the non-induced cells when subjected to the
differentiation media compared to induced cells. No lipids droplets, calcium deposits or presence
of proteoglycans were observed in non-induced cells when differentiated into the adipogenic,
osteogenic and chondrogenic lineage respectively (Fig 3.14-3.20). Cells that were induced to a
pluripotent state, then expanded and differentiated into the three lineages showed the capability
of producing the intra- and extracellular factors that characterize a successful adipogenic,
chondrogenic and osteogenic differentiation. Non differentiated controls did not present staining.

Figure 3.14 Adipogenic differentiation of induced and not induced ASCs after cell expansion
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Figure 3.15 Adipogenic differentiation of induced and not induced BMSCs after cell expansion

Figure 3.16 Adipogenic differentiation of induced and not induced fibroblast after cell expansion
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Figure 3.17 Osteogenic differentiation of induced and not induced ASCs after cell expansion

Figure 3.18 Osteogenic differentiation of induced and not induced BMSCs after cell expansion
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Figure 3.19 Osteogenic differentiation of induced and not induced fibroblast after cell expansion
Experiment 4: Effect of pluripotency induction to the tenogenic differentiation potential of
MSCs
Evaluation of the differentiation media: Gene expression
Significant up-regulation of the tenascin gene was observed in ASCs when treated (T) v nontreated (NT) were compared (expression ratio increased compared to the average expression of
the two reference genes in 2.274 folds, P=0.025). The mean fold change in BMSCs (fold change
0.412, P=0.424) and fibroblast (fold change 0.823, P=0.668) was not different between treated
and non-treated cells.
Effect of the pluripotency treated cells in tenogenic differentiation: Gene expression
Tenascin expression in ASCs 2I (double induced cells: induced to pluripotency and later
to tenogenic lineage, 2I) and fibroblast 2I compared with their respective I (only one induction:
induction to pluripotency, I) were not different (ASCs: 0.285, P=0.102 and fibroblast: 0.344,
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Figure 3.20 Chondrogenic differentiation of induced and not induced cells after cell expansion
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P=0.084) but exhibited a tendency to be down-regulated. However, tensacin expression in
BMSCs was down-regulated with a expression ratio of 0.288 (P=0.028). The expression of
tenascin in ASCs T and ASC 2I (both groups were subjected to tenogenic differentiation media,
but only one previously induced to pluripotency), cells that were induced to pluripotency
exhibited down-regulation (Expression ratio: 0.135, P=0.008). Down-regulation of tenascin was
also observed in fibroblast (fibroblast 2I v. fibroblast T, Expression ratio: 0.086, P=0.026). A
tendency to be down-regulated was detected when BMSCs were evaluated (BMSCs 2I v BMSCs
T, Expression ratio:0.143, P=0.063). Down-regulation of was also observed when the expression
in I v NT cells was compared. Reduction in tenascin gene expression was different in BMSCs
and fibroblast (BMSCs I v BMSCs NT Expression ratio:0.205, P=0.011; fibroblast I v. fibroblast
NT Expression ratio: 0.207, P=0.023). In the case of ASCs there was not statistical difference
(ASC I v ASCs NT Expression ratio: 1.077, P=0.699).
Discussion
A treatment with synthetic mRNA seems to be an interesting approach to overcome all
limitations that traditional viral reprogramming has and different sources of cells respond
similarly to this treatment. The use of MSCs had to be validated first by a screening of the
typical properties presented by these SCs, namely: cell morphology, cell surface markers and
trilineage differentiation. The cells used in the study present similar characteristics to those seen
in previous reports of equine MSCs (Vidal et al., 2006; Vidal et al., 2007; Vidal et al., 2008).
The characteristics observed in the colonies that appear in culture after the treatment with
synthetic mRNA are different to those seen in equine iPSc colonies produced by transduction
which are flatter and present a defined but irregular shape when compared to mouse iPSc
colonies (Takahashi and Yamanaka, 2006). We believe that this difference is due to the culturing
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system used in this study without feeder layers. When these cells are cultured, they present the
advantage of secreting factors such as Leukemia inhibitory factor as well as to provide a cell
adhesive layer for the colonies to attach (Silva et al., 2008). Furthermore, the grade of
undifferentiation reached with the mRNA treatment might have been different from those
reported in equine iPSCs (Nagy et al., 2011; Khodadadi et al., 2012; Breton et al., 2013), giving
another reason for the difference in colony morphology. Our approach to develop an induction of
pluripotency treatment without the use of feeder-layers resides in the need to reduce any possible
immunogenic agent that might be altering the cells used in regenerative therapy (Warren et al.,
2012). Further studies are needed to evaluate different cultures surface and culture media that
help the establishment of colonies.
Even though, the morphology of the colonies was different compared to the reported
equine pluripotent cells colonies (Saito et al., 2002; Li et al., 2006; Guest and Allen, 2007; Guest
et al., 2010; Nagy et al., 2011; Khodadadi et al., 2012; Breton et al., 2013), the fold change in
gene expression of the pluripotency genes is similar to those detected with mRNA technique in
humans (Warren et al., 2010). To date, no other report using the synthetic mRNA technique for
induction of pluripotency in equine cells has been published.
Correct localization of the proteins related to a pluripotency state in the nuclei observed
by the immunocytochemistry analysis determines not only that the synthetic mRNA used to treat
the cells is being transcribed but also that these proteins accomplished the first step to gain their
function, reach the nucleus. Plus, the stimulation of endogenous production of NANOG was
detected adding more evidence that the translated proteins had normal function.
The upregulation of the expression of the endogenous pluripotency genes detected by
qRT-PCR suggest that a reactivation of the equine genome took place. However, we cannot state
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that the cells obtained were truly iPSCs since a further characterization (teratoma formation,
chimeric embryos production and germline transmission) is needed to classify them as such. We
can account for a dedifferentiation process to a higher hierarchal potency state, but not to a
pluripotent state. This intermediate dedifferentiation state was previously described in the
literature when mouse fibroblast were partially reprogrammed to an intermediate state of
differentiation when treated with specific reprogramming small molecules (Park et al., 2011).
Not only was the gene expression modified by the treatment with synthetic mRNA, but
also the ability of the cells to be expanded without losing their multipotentiality characteristics.
This is an important outcome. Previous reports have stated that MSCs expansion in vitro reduces
their multipotentiality and regenerative capacity (Zhironkina et al., 2012). A comparative study
done in humans stated that BMSCs and ASCs became senescent at passage 7 and 8 respectively
(Kern et al., 2006), compared to umbilical cord derived stem cells that were able to maintain
their characteristics until 10 passages. In this study, ASCs and fibroblast were able to expand
until passage and still have cell viability after 21 days of culture. However, BMSCs showed a
significant decreased in their viability at day 21 that was not observed when the cells were
previously treated with the synthetic mRNA. Moreover, the multipotency characteristics were
lost when cells not subjected to the mRNA treatment were in not treated cells, while treated cells
were able to maintain them. The loss of multipotency characteristics due to cell expansion to
obtain enough material to treat a musculoskeletal injury in the horse might be overcoming by the
treatment used in this study, because trilineage differentiation and cell viability were maintained
when cells previously treated to a higher potency state with synthetic mRNA were subjected to
ten cell passages.
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Regarding the tenogenic differentiation, the expression of tenascin a gene used as a
marker of tenogenic anabolism was up-regulated when ASCs were treated with the
differentiation media. However, not observing the same changes in the other cell types suggest
that the tenogenic differentiation media and protocol needs to be adjusted to guarantee a fully
differentiation into tendon tissue. Adjustments to the differentiation into the tenogenic lineage
protocol might include the culture of cells in collagen gels subjected to a constant cycles of
tensile strain in a bioreactor (Raabe et al., 2013). When the tenogenic differentiation treatment
was used to evaluate the influence of a previous transfection with synthetic mRNA, different
results were observed since the tenascin expression of mRNA treated ASCs differentiated into
tendon (2I) did not show significant difference compared with not differentiated ones (I). This
further supports the idea that the cells reached a higher potency state with the mRNA treatment
and it was harder to differentiated when compare to the tenogenic differentiation of untreated
ASCs. This suggest that the first upregulation of tenascin presented by the ASCs might be due to
a higher level of basal expression of this gene in this cell type that would explain why was the
only cell type that responded to this tenogenic differentiation media. Plus, these findings support
the theory that when considering differentiation within the same germ layer (in this case
mesoderm) cells with a higher potency state are harder to differentiate.
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CHAPTER IV: SUMMARY AND CONCLUSION
The use of SCs in regenerative therapy is a constant expanding field not only in research
but also in clinical applications. Although these cells could be obtained from different sources,
none of them meet all the standards that satisfy physicians, researchers and public opinion to
achieve the final goal of developing a controlled treatment with SCs. Thus the idea of developing
a technique that combines the qualifying properties of MSCs and iPSCs, is appealing from every
angle.
In this study, different sources of equine MSCs were subjected to an induction of
pluripotency treatment with synthetic mRNA coding for pluripotency related proteins. We
evaluated this treatment based on a previous study performed in humans by Warren et al. 2010
since it represents a safe alternative to the viral transfection induction of pluripotency. Our
findings, suggest that this technique uses mechanisms fairly conserved across species since
upregulated gene expression of the endogenous pluripotency genes OCT4 and SOX2 was
detected in all the equine tissue sources evaluated.
Moreover, correct localization of these transcripts factors was also assessed with evidence
of functionality since an increased expression of NANOG, the other factor self regulated by the
pluripotency triad was detected by immunocytochemistry. However, further studies are needed
in order to determine if these cells could be categorized as iPSCs.
Fortunately, other positive results serve us as proof that this increased gaining of potency
is valuable, since the ability of the expansion of MSCs without losing their multipotentiality
characteristics was assessed. This represents an important finding from a therapeutic point of
view since it might solve one of the limitations of in vitro culture of MSCs. Further studies are
also needed to define a more accurate tenogenic differentiation system to obtain tenocytes in a
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successful manner. The addition of an increase in vitro expansion of cells after the treatment with
synthetic mRNA and the ability of in vitro tendon formation might allow a sequential therapy
where undifferentiated MSCs could be used in the first period of the healing process to take
advantage of their immunomodulatory and cell recruiting properties followed by the addition of
functional cells that might become part of the final reconstructed tissue.
This technique might be also appealing from an animal conservationism point of view,
because somatic cell nuclear transfer could be benefit with the treatment with synthetic mRNA
coding for pluripotency proteins. Reports in the equine specie established that incorporation of
transgenes coding for the pluripotency genes increase pregnancy rates. The alternative of using
non-DNA methods for increasing the expression as the one evaluated in this study might be more
suitable for use in a reproductive assisted technique for the preservation of endangered animals.
Overall, this technique might represent a solution to the limitations presented with the use
of SCs in regenerative therapy due to the lack of predictable outcomes. Gaining the ability of
directing cell fate to our needs might provide us with enough biological material to fill the gap in
a musculoskeletal injury as well as to fully characterize the cells before transplantation.
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APPENDIX A
Plasmid Preparation
Stab cultures containing plasmids encoding desired sequences were obtained from
Addgene (Cambridge, Massachusetts). The plasmids used were: 26816pcDNA3.3_OCT4,
26817pcDNA3.3_SOX2 and 26815pcDNA3.3_KLF4. The cultures were streaked on agar plates
containing ampicillin 100ug/ml concentration. Clones were chosen from each plate by inserting a
pipette tip into a single isolated colonies and inserting it into 3ml of Terrific Broth containing
ampicillin 100ug/ml in a 15 ml culture tube. The selected clones were cultured overnight at 37°
C shaking at 225 RPM in C24 Incubator Shaker (New Brunswick Scientific, Classic Series).
Mini Prep Isolation
Tubes containing a cloudy media post-incubation (indicating growth of the selected
clones) were used for Miniprep isolation. Minipreps were performed on using PureLink® Quick
Plasmid Miniprep Kit (Invitrogen, K2100-10). Cells were pelleted from 1.5 ml of previous
overnight culture for 1 minute at 12,000 x g in table top centrifuge (Thermo, Heraeus Pico 17
Centrifuge). Supernatant was discarded and cells were resuspended by pipetting up and down in
250 μl of Resuspension Buffer provided in the kit. The cells were then lysed with the addition of
250 μl of Lysis Solution and inverting the tubes gently to mix. The tubes were then allowed to
equilibrate for ≤ 5 minutes. The cleared lysate was then prepared for isolation with the addition
of 350 μl of Precipitation buffer and inverted 4-6 times to mix. The tubes were then centrifuged
at maximum speed of 12,000 x g for 10 minutes. The binding column was prepared by adding
500 μl of Wash Buffer and centrifuged at 12,000 x g for 1 minute. The cleared lysate was then
transferred to the prepared binding columns to bind the plasmid DNA for isolation. The column
containing the cleared lysate was centrifuged for 1 minute at 12,000 x g and the flow-through
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was discarded. Contaminants were removed by adding 750 μl of Wash Buffer to the column
followed by centrifugation at 12,000 x g for one minute. The flow through was discarded and
was centrifuged for an additional minute to remove to dry the column. Each column was
transferred to a new collection tube and the plasmid DNA was eluted in 75ul of molecular grade
water and was stored at -20°C.
Clone Selection
Diagnostic cuts in the DNA were performed with restriction enzyme XbaI (Invitrogen ,
15226-012) on each clone to determine the quality of the isolated plasmids. A master mix was
prepared (buffer provided by manufacturer, molecular grade water, XbaI restriction enzyme,
Invitrogen, Grand Island, New York) for all mini-prep isolations. The master mix was then
divided and 85ul was placed in 1.5 ml centrifuge tubes. Then, 15ul of purified DNA of each
clone was added to the tube and digestion was performed in a hot water bath of 37°C for 1 hour
and 15 minutes. The tubes were removed from the water bath and 15ul of loading buffer was
added to each tube and mixed gently by pipetting up and down. A 1% agarose gel was prepared
and 25 μl of each digest were loaded into the wells for electrophoresis evaluation. The bands
were evaluated with the additional 1 kilobase (1Kb) and 100 base pair (100bp) ladders added to
the outside lanes. Clones presenting only appropriates cut by the restriction enzyme were
selected to synthesize.
mRNA in vitro Synthesis
In order to synthesize the desired mRNA molecules a series of step are needed starting
from the purified plasmids: Linearization of the plasmid, Capped Transcription Reaction,
Poly(A) tail synthesis and Recovery of the RNA.
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Linearization of the Plasmids
Plasmids containing template sequence were linearized using restriction enzyme XbaI. The
restriction digest was terminated with the addition of 1/10th the volume of 5 M NH4 acetate and
2 volumes of ethanol. The solution was mixed well and stored in -20°C for 15 minutes. The
DNA was pelleted by centrifugation at 13,000 x g for 15 minutes. The supernatant was removed
and the tube centrifuged again, and any residual fluid was removed with a fine-tipped pipet. The
pellet was resuspended in 6 μl DNAse free water and was carried over into the mMESSAGE
mMACHINE® T7 transcription Kit (Invitrogen, AM1344) for the Capped Transcription
Reaction, following the next protocol:
mMessage mMachine® t7 Transcription Kit Protocol
1. Thaw frozen reagents. Place RNA Polymerase Enzyme Mix on ice. Vortex the 10X Reaction
Buffer and 2X NTP/CAP to ensure contents are resuspended and place the 2X NTP/CAP on ice.
Centrifuge in microfuge briefly prior to removing caps.
2. Assemble transcription reaction at room temperature. A cocktail of the modified bases was
prepared containing 15mM of 5-methylcytidine-5’-triphosphate (5-Methyl-CTP, TriLink
Biotechnologies,

N-1014)

15mM

pseudouridine-5’-triphosphate

(Pseudo-UTP,

TriLink

Biotechnologies, N-1019), 15mM ATP, 3mM GTP and 12mM N7-Methyl-3’-O-MethylGuanosine-5’-Triphosphate-5’-Guanosine

(Anti

reverse

Cap

analog,

ARCA,

TriLink

Biotechnologies, N-7003). Add the water and ribonucleotides to the tube prior to adding the 10X
Reaction Buffer, followed by the addition of linear DNA template and Enzyme Mix: 10 µl of
modified bases cocktail, 2 µl 10X Reaction Buffer, 6 µl (0.1-1ug) Linear DNA template, 2 µl
Enzyme Mix.
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3. Mix thoroughly by gently flicking the tube or pipetting up and down. Centrifuge briefly to
bring the reaction to the bottom of the tube.
4. Incubate at 37°C for 2 hours for maximum yield.
5. Reaction goes immediately into Poly(A) Tailing Kit.
The previously completed 20ul reaction was carried over to the Poly (A) Tailing Kit (Applied
Biosystems AM1350) for further RNA packaging.
Ambion® Poly(a) Tailing Kit Protocol
1. Begin with a completed, room temperature, mMessage mMachine reaction (20 µl in 1.5ml
tube).
2. Kept at room temperature, add the following reagents in the order they are listed to the 20 µl
mMessage mMachine reaction: 20 µl mMessage mMachine reaction, 36 µl Nuclease-free water,
20 µl 5X E-PAPBuffer, 10 µl 25 mM MnCl2, 10 µl 10 mM ATP.
4. Add 4 µl of E-PAP and mix gently. The final reaction should be 100ul.
5. Incubate for 1 hour at 37°C.
6. Reaction can go directly into the MEGAclear™ Kit procedure or can be placed on ice or
stored at -20°C until for later use.
The tailing reaction was purified using MEGAclear Kit (Applied Biosystems AM1908).
Megaclear™ Kit Procedure
1. Begin with 100 μl Poly(A) Tailing Reaction (or bring RNA sample up to 100 μl by adding
Elution Solution and mix gently).
2. Add 350 μl of Binding Solution Concentrate and mix gently by pipetting.
3. Add 250 μl of 100% ethanol and mix gently by pipetting.
4. Insert a filter cartridge into a Collection and Elution tube supplied by the manufacturer.
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5. Apply the RNA sample to the filter cartridge.
6. Centrifuge at 10,000-15,000 x g for 1 minute with the cap of the tube open to pass mixture
through the filter.
7. Discard flow-through and reuse the Collection and Elution Tube during the following wash
steps.
8. Be sure ethanol has been added to the wash solution before use. Apply 500 µl Wash Solution
and centrifuge at 10,000-15,000 x g for 1 minute to pass the Wash Solution through the filter.
9. Repeat with a second 500 µl Wash Solution.
10. Discard flow-through and centrifuge for 30 seconds at 10,000-15,000 x g to remove any
Wash Solution.
11. Put the cartridge in a new Collection Tube. Elute RNA with 50 µl of TE: Pre-heat 110 µl of
TE to 95°C. Apply 50 µl of pre-heated Elution Solution to the center of the filter and close the
cap. Centrifuge for 1 minute at 10,000-15,000 x g. Repeat the elution to maximize recovery with
a second pre-heated 50 µl of TE into the same tube.
The synthetic mRNA was then quantified using NanoDrop 1000 Spectrophotometer using TE as
the blank for the machine. The solution was then diluted with an adequate volume of TE to
obtain a working concentration of 100 ng/ml.
Cell Collection
Cells from different types of tissue were collected from 4 euthanized horses due to clinical
reasons. Collections of MSCs were performed from the Bone Marrow (from the sternebrae) and
Adipose tissue (from the base of the tail) following the next detailed protocols. Fibroblasts were
cultured from biopsied dermis tissue. They were cultured in stromal media containing: HyClone
Ham’s F12/DMEM (HyClone, SH30023.01) medium containing 10% FBS (Atlanta Biologicals,
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S12450) and 2% antibiotic/antimycotic solution (MP Biomedicals, 1674049) in 5% CO2 in
humidified air at 38°C. The primary culture was replicated before cells reached confluence with
0.25% Trypsin (Gibco®, 25200-0569 until P2 and frozen in 90% FBS with 10% DMSO and
stored in cryogenic vials at -80°C. Vials were revitalized within a month of cryopreservation.
After revitalization all plates were seeded at a number of 5000cells/cm2. All cells were further
culture in 5% CO2 in humidified air at 38°C, except during the pluripotency induction treatment
when cells were place in a modular incubator containing 5% CO2, 5% O2 and 90%N2 at 38°C.
Isolation of Adipose Derived MSCs
1. Use aseptic technique to collect the sample. Clip the area around the base of the tail and make
three washes with 3% Clorehexidine in distilled water and three washes with 70% ethanol in
distilled water.
2. Transport in PBS supplemented with 5% FBS and penicillin and streptomycin (1%) to the lab
in order to process.
3. Wash the tissue collected 3 times with PBSs and put in Erlenmeyer or 50 ml centrifuge tube.
4. Mince the tissue with a scalpel blade to loosen the structure of the fat.
5. Add 25ml of 0.25% Collagenase I (Worthington, 4197) solution in PBS with 0.25% Bovine
Serum Albumin (Sigma, 85040C).
6. Put the Erlenmeyer or tube in shaker at 200 rpm for 2 hours at 37°C.
7. If you use an Erlenmeyer place everything in a 50 ml tube. Add 15 ml of PBS. Shake the tube
vigorously with your hand for 1-2 minutes.
8. Centrifuge at 1,600 rpm for 5 minutes.
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9. In case oil has been separated (the top interface) from the rest of the sample (fat tissue and
cells detached), remove it by aspiration (taking care not to aspirate the floating tissue) shake
again the tube vigorously with your hand for 1-2 minutes.
10. Centrifuge at 1,600 rpm for 5 minutes.
11. Take out all the floating and big pieces of tissue with a sterile needle or pliers.
12. Shake again for 1 minute (not vigorously) just to homogenize the pellet with the solution.
13. Filter the solution with a disposable 100 µm filter
14. Centrifuge at 1,600 rpm for 5 minutes.
15. Discard everything keeping the pellet.
16. Resuspend in culture media and place in T12.5 flask or 10 cm diameter Petri dish.
17. Change the media 24 hours later. Viable cells should be attached at that time.
Isolation of Bone Marrow Derived MSCs
1. Routine procedure is used to harvest sternal bone marrow with a 8.89 cm 10 gauge bone
marrow Jamshidi® needle in a sterile manner.
2. Samples are collected with a 50ml Luer lock syringe containing 2 ml of heparin solution (300
IU/ml).
3. Immediately after collection put the sample into a 50 ml conical centrifugation tube.
4. Add approximately 20 to 25 ml of stromal medium to each 50 ml centrifugation tubes
containing the bone marrow and mix gently.
5. Prepare one 50 ml centrifugation tube containing 15ml of Ficoll-Paque® PLUS (Stem Cell
Technologies, 07975).
6. Layer bone marrow cell suspension mixture carefully over the Ficoll without disrupting the
interface.
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7. Centrifuge the bone marrow aspirate/Ficoll gradient for 30 minutes at 1400 rpm. Set the
centrifuge brake to 1 so that interface does not disrupt when slowing down.
8. Harvest the faint layer of nucleated cells just above the Ficoll layer using a sterile pipette until
a sharp contrast between the Ficoll layer and overlying supernatant layer becomes apparent.
9. Pool the cells collected from above the Ficoll into a sterile 50 ml centrifuge tube containing
15ml of stromal media and centrifuge at 1200 rpm for 10 minutes to sediment the cells.
10. Plate the cells in T75 flask or 10cm diameter Petri
11. Incubate at 37°C in 5% CO2 humidified atmosphere.
12. Allow the mesenchymal stromal cells (stem cells) to adhere to the plastic during a delayed
culture period of 5- 6 days duration.
13. On day 5 or 6 remove 70 to 80 % of the culture media and replace with fresh stromal
medium.
Lipofectamine Transfections
Cells plated in a 24w plate at 70% confluency were used for transfection. Specific
synthetic mRNA was diluted in Opti-MEM I Medium (Invitrogen, 31985-062) in 15ml conical
tubes at a final amount of 2pmol of RNA per well and the Lipofectamine RNAiMAX Reagent
(Invitrogen,

13778-150) was

prepared following manufacturer

protocol with

slight

modifications. At day 7 and 14 cells were trypsinized and a sample of 40,000 cells was taken to
seed the Chamber slide for immunocytochemistry.
Lipofectamine® RNAiMax Reagent Transfection Protocol
1. Plate target cells 24-hours prior to transfection in 500 µl growth medium each well of a 24
well plate. Cell should be 50-70% confluent for transfection.
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2. Dilute synthetic mRNA in 50 µl of Opti-MEM® I Medium without serum per well (always
make for an extra well to account for pippeting error) in a 15 ml conical tube and mix gently.
Label as Tube 1.
3. Gently mix Lipofectamine® RNAiMAX Reagent prior to use. Dilute 1 µl of Lipofectamine®
RNAiMAX Reagent in 50 µl of Opti-MEM® I Medium per well in a separate 15 ml conical
tube. Label as Tube 2.
4. Combine the contents of Tube 2 into the contents of Tube 1 and mix gently. Incubate for 15
minutes at room temperature.
5. Add adequate amount of RNA-Lipofectamine® complexes to each well (100 µl) and mix
gently by rocking the plate back and forth several times. The total volume in the well should be
roughly 600 µl.
6. Incubate in CO2 incubator at 37°C.
7. Repeat transfection 24 hours later, everyday for 14 days. Change medium before making a
new transfection.
Evaluation of Induction of Pluripotency Treatment
To determine if the treatment with synthetic mRNA was successful, quantitative and
qualitative assessments of gene expression and protein localization were performed.
Concentration of endogenous equine transcripts was determined with qRT-PCR with specific
primers design and PCR conditions set to detect the activation of the equine endogenous
pluripotent genes and not the human exogenous sequences. Treated and controls cells were
subjected to the RNA isolation procedure, cDNA synthesis and qRT-PCR.
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RNA Isolation
Cells were trypsinized from each well and two replicates of each group were combined
(approximately 1x106 cells) into one 1,5ml tube each for each group. The cells were pelleted and
subjected to the mRNA isolation proctol using Dynabeads®mRNA DIRECT™ Kit (Ambion,
61011) following the “standard” procedure. The mRNA was eluted in 30 ul of DNAse free
water.
Dynabeads®mRNA Direct™ Kit Protocol
1. Harvest cells from culture well and pellet as per standard procedure
2. Add 1250 µl of Lysis/Binding buffer (100 mM Tris-HCL, pH 7.5, 500 mM LiCl, 10 mM
EDTA, pH 8, 1% LiDS, 5 mM dithiothreitol) to a fresh cell pellet with repeated passage of the
solution through a pipette tip to obtain complete lysis. The formation of a viscous solution
confirms complete lysis.
3. Perform DNA-shearing step forcing the lysate strip cells using a 21-gauge needle 5 times
using a 1–2 mL syringe. The reduction in viscosity should be noticeable. Repeated shearing
causes foaming of the lysate due to detergent in the buffer, however, this should not affect the
mRNA yield. The foam can be reduced by a 30 second centrifugation. The lysate can be frozen
and stored at –80°C for later use.
4. Resuspend Dynabeads® Oligo(dT)25 thoroughly before use.
5. Transfer 250ul Dynabeads® Oligo (dT)25 stock tube to an RNase-free 1.5-mL microcentrifuge
tube and place the tube on a magnet . After 30 seconds (or when the suspension is clear), remove
the supernatant. Remove the tube from the magnet and wash the beads by resuspending in an
equivalent volume of fresh Lysis/Binding Buffer.
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6. Remove the Lysis/Binding Buffer from the prewashed Dynabeads® Oligo(dT)25 by placing on
the magnet for 30 seconds, or until the suspension is clear and discard the supernatant.
7. Remove the microcentrifuge tube from the magnet and add the 1250 µl of sample lysate.
8. Resuspend beads completely into sample lysate and incubate with continuous mixing (rolling
mixer) for 5 minutes at room temperature. Rotate the tube after the first 2.5 minutes of mixing.
This allows the polyA tail to hybridize to the beads.
9. Place the vial on the magnet for 10 minutes and remove supernatant.
10. Wash beads/mRNA complex twice in 1000 µl Washing Buffer A (10 mM Tris-HCl [pH 7.5],
0.15 M LiCl, 1 mM EDTA, 0.1% LiDS) at room temperature. Place on magnet to separate beads
from solution between each wash step.
11. Wash beads/mRNA complex in 1000 µl Washing Buffer B (10 mM Tris-HCl [pH 7.5], 0.15
M LiCl, 1 mM EDTA) at room temperature. Transfer to a new tube. Use the magnet to separate
the beads from the solution.
12. Wash again beads/mRNA complex with 1000µl Washing Buffer B. Use the magnet to
separate the beads from the solution.
13. Elute the RNA from the beads by adding 27 µl of nuclease-free water, incubate at 75°C for 2
minutes. Immediately place tube on magnet, and transfer supernatant to a new RNase-free tube.
14. Take 2 µl of the sample to measure mRNA concentration and purity in the NanoDrop 1000.
15. Use the isolated RNA directly into cDNA protocol or keep them at -80°C.
Conversion of mRNA into cDNA
To perform quantitative PCR all of the samples were converted to cDNA with the two
step reverse transcription kit of QIAGEN (Quantitect® Reverse transcription Kit, 205310) that
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eliminates genomic DNA. Conversion to cDNA was performed in a bench-top Bio-Rad MJ Mini
Personal Thermocycler
Quantitect® Reverse Transcription Kit Protocol
1. Use fresh RNA or thaw template RNA on ice . Thaw gDNA Wipeout Buffer, Quantiscript
Reverse Transcriptase, Quantiscript RT Buffer, RT Primer Mix, and RNase-free water at room
temperature (15–25°C). Mix each solution by vortexing the tubes. Centrifuge briefly to collect
residual liquid from the sides of the tubes, and then store on ice.
2. Prepare the genomic DNA elimination reaction on ice: Add 2 µl gDNA Wipeout Buffer 7x to
12 µl of RNA sample (check that the final amount of RNA should not exceed 1ug per reaction, if
it does use less volume of the sample and complete with RNase-free water). Mix and then store
on ice.
3. Incubate for 2 minutes at 42°C. Then place immediately on ice.
Note: Do not incubate at 42°C for longer than 10 minutes.
4. Prepare the reverse-transcription master mix on ice: Quantiscript Reverse Transcriptase 1 µl,
Quantiscript RT Buffer 5x 4 µl and RT Primer Mix 1 µl per reaction tube. Prepare one reaction
more for pipetting error. Add 6 µl of the mix to the 14 µl from step 3, obtaining a final volume of
20 µl.
5. Incubate for 30 minutes at 42°C to increase cDNA yields.
6. Incubate for 3 minutes at 95°C to inactivate Quantiscript Reverse Transcriptase.
Calibrator Development
To evaluate the gene expression of the pluripotency genes with qRT-PCR primers need to
be validated (see Appendix B) for what is required a positive control to develop the standard
curves. The positive control is also going to be use on every qRT-PCR to asses that the reactions
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during amplification occurred normally. This positive control was developed by mixing mRNA
extracted from horse day 7 blastocysts and mRNA from all the cell types used in the experiment.
This mRNA mixture was then transformed into cDNA as described previously. The positive
control was then “spiked” with purified PCR product (QIAquick PCR Purification Kit) of the
specific genes, leading to the formation of a “calibrator”. The genes include both the genes of
interest, OCT4, SOX2, and KLF-4, as well as housekeeping genes polyadenylate polymerase and
hypoxanthine phosphoribosyltransferase-1. The calibrator contains genes of interest at a final
concentration of 2 pg/μl and the housekeeping genes at a final concentration of 0.2 pg/μl. The
same procedure was performed for the development of a calibrator to detect the expression of the
tenogenic related genes. In this case the positive control was mRNA extracted from a section of
5 mg of the superficial digital flexor tendon of a horse mixed with mRNA from all the cell types
used in the experiment. Validation of the tenascin primers was developed using the same
procedures (see Appendix B). In order to develop this calibrator mRNA extraction using the
RNeasy® Plus Micro kit (QIAGEN, 74004) and RT-PCR were performed following these
detailed protocols.
RNeasy® Plus Mini Kit (QIAGEN)
1. Different procedures were performed to obtain an homogenized lysate depending on the
sample type.
For processing the tendon: In order to grind the tendon a TissueRuptor was used. The
TissueRuptor is a rotor–stator homogenizer that thoroughly disrupts and simultaneously
homogenizes single tissue samples in the presence of 350 µl Buffer RLT Plus in 2 minutes.
For processing the blastocysts: Disrupt cells with the addition of 75 µl Buffer RLT Plus. Mix by
vortexing or pipetting up and down. Centrifuge for 5 minutes at 10,000 rpm to remove the
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capsule. Transfer the supernatant to a new tube. Adjust the volume to 350 µl of Buffer RLT Plus.
Vortex for 1 minute to homogenize.
For processing the cell cultures: Harvest cells by trypsinization and pellet. Completely remove
supernatant. Disrupt cells with the addition of 350 µl Buffer RLT Plus. Mix by vortexing or
pipetting up and down. Homogenize lysate by passing it through a 20-gauge needle 5 times in an
RNase-free 1 ml syringe.
2. Transfer homogenized lysate to a gDNA Eliminator spin column placed within 2 ml collection
tube. Centrifuge 30 seconds at 10,000 rpm and discard column. Collection tube should contain
flow-through to be used in following steps.
3. Add 350 µl of 70% ethanol to the flow-through in the collection tube. Mix by pipetting up and
down.
4. Transfer 700 µl of sample to RNeasy® spin column placed within a 2 ml collection tube and
close lid. Centrifuge for 15 seconds at 10,000 rpm. Discard flow-through.
5. Add 700 µl Buffer RW1 to the RNeasy® spin column placed into previous collection tube.
Close lid and centrifuge for 15 seconds at 10,000 rpm. Discard flow-through.
6. Add 500 µl Buffer RPE to RNeasy® spin column and close lid. Centrifuge for 15 seconds at
10,000 rpm. Discard flow-through.
7. Add 500 µl Buffer RPE to RNeasy® spin column and close lid. Centrifuge 2 minutes at 10000
rpm to ensure removal of ethanol. Remove column carefully not coming in contact with flowthrough.
8. Place RNeasy® spin column into a new 1.5 ml collection tube and add 17 µl RNase-free water
directly to spin column membrane. Close lid and centrifuge for 1 minute at 10,000 rpm for RNA
elution. Repeat with an additional 17 µl to maximize recovery.
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Retro Transcriptase Polymerase Chain Reaction
RT-PCR was used to determine the correct size amplicon produced by the primers
designed (see Appendix B), to perform a temperature gradient to evaluate the annealing
temperature in order to detect the endogenous expression of equine pluripotency genes (see
Appendix B), and to have enough amplicon to make the “calibrator”. Each PCR reaction
consisted of 25 μl JumpStart™ REDTaq® ReadyMix™ PCR Reaction Mix (Sigma Aldrich,
P0982), 4 μl forward primer (5 mM), 4 μl reverse primer (5 mM), 2 μl cDNA, and 15 μl dH20
for a total of 50 μl. The PCR were carried out in a Bio-Rad MyiQ thermocycler. The final PCR
products were evaluated by gel electrophoresis using a 2% agarose gel with 1µl of propidium
iodide (PI, Sigma, P4864) including a 100bp ladder (New England Bio Labs, N3231L) on the
outside lanes. The gel was observed under UV light using BIO-RAD Universal Hood II and
pictures were taken with Quanity One Analysis Software.
RT-PCR Protocol
1. Each reaction is carried out in a total of 50 µl. Mix 25 µl Jumpstart Red Mix, 2 µl of (10 mM)
forward primer, 2 µl of (10 mM) reverse primer, 11 µl of water, and 10 µl of sample cDNA.
Prepare master mixes prior to avoid repeated pipetting.
2. Place tubes into thermocycler with the following program:
Step 1: Hotstart: 94°C for 2 minutes
Step 2: 30 repeats of: Denaturation: 94°C for 30 seconds
Annealing: 60°C for 30 seconds
Extension: 72°C for 1 minute
Step 3: Final Extension: 72°C for 5 minutes
Step 4: Hold: 4°C indefinitely
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To determine the annealing temperature that only amplified the equine sequence the temperature
gradient used was: 60°C, 62.1°C, 63.9°C, 66.4°C, 68.3°C and 70°C
3. Remove tubes from thermocycler and add 25 µl of each PCR product to a 2% agarose gel for
electrophoresis.
Purification of PCR Products
The “calibrator” used to construct the standard curves for qRT-PCR was spiked with PCR
amplicons. The PCR products were purified to eliminate all those reagents that were used for
RT-PCR (purified from primers, nucleotides, polymerases and salts) with QIAquick PCR
Purification Kit (QIAGEN, 28104) following the next protocol.
QIAquick PCR Purification Kit Protocol:
1. Add 5 volumes of Buffer PB to 1 volume of the PCR sample and mix. (Normally, add 100 μl
of Buffer PB to 20 μl PCR sample).
2. Place a QIAquick spin column in a provided 2 ml collection tube.
3. To bind DNA, apply the sample to the QIAquick column and centrifuge at 10,000 rpm for 60
seconds.
4. Discard flow-through. Place the QIAquick column back into the same tube. Collection tubes
are re-used to reduce plastic waste.
5. To wash, add 0.75 ml Buffer PE to the QIAquick column and centrifuge at 10,000 rpm for 60
seconds.
6. Discard flow-through and place the QIAquick column back in the same tube. Centrifuge the
column at 10,000 rpm for an additional 1 minute.
7. Place QIAquick column in a clean 1.5 ml microcentrifuge tube.
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8. To elute DNA, add 30 μl of RNase free water (pH 7.0–8.5) to the center of the QIAquick
membrane, let the column stand for 1 minute, and then centrifuge at 10,000 rpm for 1 minute.
qRT-PCR
Quantitative PCR was used to evaluate gene expression in the target cells. Total RNA
was extracted from cells in all wells using Dynabeads®mRNA DIRECT™ Kit as described
previously. The final elution into 27 μl of RNase free water was used to determine the
concentration and purity of the sample (2 μl of sample), to generate cDNA with the Quantitect®
Reverse transcription Kit (12 μl of sample) and the rest (13 μl of sample) was stored at -80°C as
backup. The quantitative PCR reactions were performed in a final volume of 20 μl containing 10
μl of Bio-Rad SsoFast™ EvaGreen® Supermix (Bio-Rad, 172-5200) 2 μl of forward primer, 2 μl
of reverse primer 1 μl of cDNA sample and 5 μl of nuclease-free water. Master mixes were
prepared per primer sets and per sample triplicate. A no-template reaction was used as a negative
control, replacing the sample with nuclease-free water. The “calibrator” was used as positive
control. Amplification, standard curves and gene expression efficiency were normalized against
housekeeping genes PAP and HPRT-1 as internal controls. The qRT-PCR were carried out in a
Bio-Rad MyiQ Single color Real-time PCR detection system with a Bio-Rad MyiQ Optical
System Software v1.1. Gene expression
qRT-PCR Protocol
1. Set up plate template.
2. Prepare master mixes for each gene. Each reaction is carried out in a 20 µl reaction (10 ul of
SsoFast™ Evagreen Supermix (Bio-Rad Laboratories, Inc. Hercules, CA, USA), 5 µl of
nuclease-free water, 2 µl of (5 mM) forward primer, 2 μl of (5 mM) reverse primer, and 1 µl of
sample cDNA, calibrator cDNA, or water as negative control.
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3. Add 20 µl of each reaction into a single well of a 96-well plate with the designated plate setup. Cover with sealing tape supplied by plate manufacturer. Be sure to completely seal each well
using the rubber scraper.
4. Place 96-well plate into thermocycler and run the following program:
Step 1: Hotstart: 95°C for 1 minute
Step 2: 40 repeats of: Denaturation: 94°C for 5 seconds
Annealing and extension: 60°C for 30 seconds
Step 3: 95°C for 1 minute
Step 4: 55°C for 1 minute
Step 5: 80 repeats of increasing 0.5°C starting on repeat 2 55°C for 10 seconds.
Step 6: Hold: 4°C indefinitely
Data collection and real time analysis were carried out in Step 2. Melt curve data collection and
analysis were carried out in Step 5.
Different annealing temperatures were used depending on the gene evaluated: OCT4 67°C, KLF4 65°C, SOX-2 60°C, HPRT-1 60°C, PAP 60°C and TNC 60°C. Each plate was run for a
specific gene.
5. Evaluate post-run data for analysis and melting curve. If a calibrator dilution was performed,
evaluate Standard Curve Efficiency, PCR Amp/Cycle graph, and Melt Curve Analysis.
Immunocytochemistry
Specific localization of the pluripotency related proteins was assessed with
Immunocytochemistry using the Fluorescent Human ES/iPS cell characterization kit (Milipore,
scr078) for detection of OCT4, Sox-2 and NANOG expression following the next protocol for
cells cultured in a Chamber slide (Glass chamber Slide system NUNC, 4wells, 0.5–0.9 ml/well
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of media, 9 x 20mm, 1.8 cm2, cat# 177399). The same procedure was done to evaluate cell
morphology with the 488 phalloidin F-Actin (Molecular Probes®, A12379) staining, except that
the Blocking step was omitted and the incubation with the antibody was replaced with incubation
with 488 phalloidin F. Nuclei staining were performed with DAPI (contained in Human ES/iPS
cell characterization kit) or Hoechst 33258 (Sigma, 94403) Avoid confluence, since cells should
be spaced enough to identify each cell, but culture them for enough time to have some cells close
to one another to take pictures. Pictures were taken using a Leica DM4500B microscope with a
Leica DFC480 camera using a fluorescence lamp Leica EL6000.
Immunocytochemistry Protocol
1. Aspirate culture media. Wash 3 times with PBS to remove culture media. (Aspirate with
vacuum from one the side to avoid touching the cells on the bottom of the slide)
2. Fix cells in 4% paraformaldehyde (PFA) in PBS for 15 minutes at room temperature.
3. Aspirate solution and Wash 3 times with PBS (5 minutes per wash).
4. Permeabilization: Add approximately 300 μl (to cover the entire well) to each well of
Permeabilization solution (0.2% Triton X-100, and 0.05% NaN3 in 1X PBS). Incubate for 20
minutes at room temperature.
5. Aspirate solution and Wash 3 times with PBS (5 minutes per wash).
6. Blocking: Add 300 μl to each well of Blocking solution (3% Normal Goat or Donkey Serum,
0.2% Triton X-100, and 0.05% NaN3 in 1X PBS). Incubate at 37°C for 30 minutes.
7. Before the end of the incubation time, prepare 1:100 dilutions of the conjugated antibodies in t
blocking buffer (protected from light).
8. Aspirate solution and Wash 3 times with PBS (5 minutes per wash).
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9. Add the 1:100 diluted antibodies to the designated well. Incubate for 2 hours at room
temperature. Cover the Chamber slides with tin foil to protect from the light. Prepare to use 300
μl of antibody solution for each well.
10. Aspirate solution and Wash 3 times with PBS (5 minutes per wash).
11. Prepare the DAPI dye. Dilute the DAPI in 1X PBS at 1:1000 dilution.
12. Counterstaining: Add 300 μl of the DAPI solution and incubate at room temperature for 5
minutes covered from light.
13. Aspirate solution and Wash 3 times with PBS (3 minutes per wash).
14. Removal of the chamber and mounting: Remove the chamber from the slide using the
“lifting device”. Be sure that the device is free from any rubber from previous detachments.
Pressure the device between the chamber and the slide firmly and slide it to the other end just to
lift the plastic chamber. In order to remove the sealing rubber is better to grab it with a mouse
tooth forceps from one end and lift the rubber firmly while holding down the slide (wear
googles). Make sure to remove all the rubber that is sealing the chamber (if not it would make
difficult the mounting of the cover slide). To remove the extra rubber attached to the slide, use a
pliers and a scalpel blade to peel it off. Use the vacuum system with a tip to remove the extra
PBS in the slide. Do it from the sides setting the slide in a vertical position over the longest
border of it.
To mount the cover slide, put a drop (10 μl) of glycerol in the area where each of the
wells was (4 drops in total). Place the slide in the counter and gently put the slide on top. The
weight of the cover slide should be enough pressure to avoid bubble formation
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Flow Cytometry
The multipotentiality of the cells used in the different experiments was assessed in a first
instance with Flow cytometry using specific antibodies against cell surface markers: αCD44
clone:HR-BAG40a (Washington State University,
BOV2037),

αCD105-PE

Monoclonal antibody center cat#:HR-

clone:SN6.(eBioscience,

cat#12-1057),

αCD90-PE

clone:

YKIX337.217 (eBioscience, cat#12-5900) and αCD29 clone:18/CD29 (BD Transduction
Laboratories, cat#610468). For those unconjugated antibodies a secondary antibody was used
(anti-mouse IgG whole molecule FITC conjugated, Sigma, F9006). For each sample/antibody at
least 2x105 cells at P2 were used. The flow tubes used were polysterene round bottom 5ml (BD
Falcon 352054).
Flow Cytometry Protocol
1. Trypsinize the cells (200.000 cells/sample-antibody). Add PBS to dilute the trypsin.
2. Transfer everything to 15 ml centrifuge tubes
3. Centrifuge 10 minutes 1,400 rpm. Descart supernant (Gently pour instead of aspirating)
4. Resuspend in PBS. The volume will depend on how many samples (antibodies to test).
Usually 200 µL/sample
5. Aliquot cells in flow tubes (it is good practice to have the tubes uncap and the antibodies in
order. Cap them when you put the antibody, just to keep track of what you are doing)
6. Centrifuge with a quick spin the whole tube of antibody.
7. Add 1µL of (primary) antibody in each sample. Vortex (10-20sec). Incubate for 30 minutes in
the dark at room temperature.
8. Add PBS: 3 ml/sample.
9. Centrifuge 10 minutes 2,000 rpm.
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10. Observe the pellet on the bottom of the tube.
11. Descart supernant (Gently pour instead of aspirating. There might be a leftover of PBS that is
enough to resuspend the cells with formalin or add secondary antibody).
12. If no secondary antibody is needed add 30-50 µL of 1-2% PFA in PBS, Vortex and keep it in
4˚C until flow cytometry. The samples will be good for up to one week.
13. If secondary antibody is needed, add 1 µL in each sample. Vortex. Incubate for up to 30
minutes in the dark. Do not incubate longer than that.
14. Add PBS: 3 ml/sample.
15. Centrifuge 10 minutes 2,000 rpm.
16. Observe the pellet on the bottle of the tube.
17. Descart supernant (Gently pour instead of aspirating. There might be a leftover of PBS that is
enough to resuspend the cells with formalin) add 30-50 µL of 1% PFA in PBS, Vortex and keep
it in 4˚C until flow cytometry.
Differentiation into Specific Lineages
Cells used in the experiments were further characterized with trilineage differentiation
induced with media supplementation at P2. Furthermore, assessment of maintenance of the
multipotency characteristics after induction of pluripotency treatment was performed following
the same protocol. In this last case cells were expanded until P10. Control cells were culture with
stromal media. Differentiation into osteogenic, adipogenic and chondrogenic lineages were
evaluated with Oil Red O staining, Alcian Blue staining and von Kossa staining respectively.
Furthermore, differentiation into the tenogenic lineage was induce and evaluated with qRT-PCR
as described previously. Before induction of differentiation into the specifics lineages evaluated,
cells were cultured until 80% confluence in a 12 well plate for the adipogenic, osteogenic and
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tenogenic differentiation, and in form of a pellet in15ml tubes for the chondrogenic
differentiation.
For adipogenic differentiation the induction media consisting of: DMEM-Ham’s F12, 10% FBS,
33 μM biotin (Sigma, B4639), 17 μM pantothenate (Sigma, P5155), 2 μM insulin (Sigma,
I5500), 1 μM dexamethasone (Sigma, D4902), 500 μM isobutylmethylxanthine (Sigma, I5789),
and 5 μM rosiglitazone (AK Scientific, 70325) was used during 7 days in cells in a monolayer.
Then, the cells were cultured 14 days more in the same media without isobutylmethylxanthine
and rosiglitazone. For osteogenic cells were cultured in monolayer for 21 days in this
differentiation medium: DMEM-Ham’s F12, 10% FBS, 10 mM ß-glyceropospahte (USB
Corporation, 21655), 100 nM dexamethasone and 0.25 mM ascorbic acid 2-phosphate. For
tenogenic lineage cells in monolayer were differentiated with a two step protocol. First, cells
were incubated for 24 hours with stromal media supplemented with 10 ng/ml of BMP-12
(BioVision, 4572) reported to augment the formation of tendon-like tissue in adult multipotent
stromal cells in human. Then, cells were cultured in DMEM, 15% FBS, 0.34 mM proline and
0.17 mM ascorbic acid (tenogenic differentiation media) for 21 days. For chondrogenic
differentiation pellet cultures were made by centrifuging aliquots of 2.5x105 cells. Cells were
resuspended in 1ml of pre-warmed stromal media and centrifuge at 1,500 rpm (200 x g) for 5
minutes at room temperature. Media was discarded and the pellet was resuspended cells in 500
µl of chondrogenic differentiation media. The tube cap was loosen to allow gas exchange and
incubate at 37ºC and 5% CO2. After 1-2 days the cell pellet formed a round ball of
approximately 1-2 mm in diameter. Caution is needed when replacing the medium to avoid
aspirating the pellet. The chondrogenic differentiation media used to maintain the pellets for 21
days was DMEM high glucose supplemented with 100 nM dexamethasone, 0.25 mM ascorbic
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acid 2-phosphate (Sigma, A8960), 40 µg/ml proline (Sigma, P0380) and 10 ng/ml TGF-ß (R&D
System, 243-B3). All the cell culture differentiation media were renew every 3-4 days. Control
cells were cultured in stromal media for the same period and stained as described previously.
Evaluation of Trilineage Differentiation
Evaluation of the differentiation into the three lineages (osteogenic, adipogenic and
chondrogenic) was performed with specific staining following the next detailed protocols.
Pictures were taken under a Olympus CKX41 stereoscopic microscope using a Olympus DP21
camera incorporated.
Osteogenic Differentiation: Alizarin Red Staining Protocol
1. Rinse with 150 mM NaCl three times each well that is going to be stained (approximately 1 ml
per rinse per well). Do not use PBS at any time during this protocol; it will create an artifact in
your data.
2. Fix in ice cold 70% ethanol. Place plate for 1 hour at 4oC.
3. Prepare 2% alizarin red solution in distilled water (0.2 g Alizarin Red, Sigma A5533, in 10 ml
distilled water). Adjust pH to 4.1 to 4.3 with dilute NaOH. Filter the solution in a two step
procedure. First, through a 100 m filter and then through a 0.22 m syringe filter. This can be
stored at room temperature covered with aluminum foil.
4. Remove ethanol from the well. Rinse with water three times. Cover the well with 2% alizarin
red solution; use 1 ml per well on a 12 well plate. Allow to stain for 10 minutes at room
temperature. Observe under a microscope to determine extent of staining.
5. Rinse the wells 5 times with water. Rinse a final (6th) time for 15 minutes in distilled water.
Remove this last rinse and add 1 ml of distilled water to take pictures.
6. Photograph immediately at this step for documentation at selected magnification.
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Adipogenic Differentiation: Oil Red O Staining Protocol
1. Prepare stock solution of Oil Red O. Weigh out 0.5 grams Oil Red O (Sigma, O0625).
Dissolve in 100 ml isopropanol. Filter the solution in a two step procedure. First, through a 100
m filter and then through a 0.22 m syringe filter. Store at room temperature as stock solution.
2. Take 6 ml of Oil Red O stock solution. Add 4 ml of distilled water. Stand 1 hour at room
temperature. Filter through 0.2 μm filter.
3. Rinse the 12 well plate three times with PBS.
4. Fix cells by adding 1ml of 1% PFA in PBS. Place plate at 4o C for 1 hour.
5. Remove all formaldehyde from well. Well should be dry after fixation and removal. Let sit the
plate under the hood until the surface of the well is dry.
6. Add 1ml of Oil Red O to each well for 15 minutes at room temperature.
7. Rinse three times or more (the rinse should become completely clear) with 1 ml distilled
water. Remove the last rinse and add 1 ml of distilled water to take pictures.
8. Photograph immediately at this step for documentation at selected magnification.
Chondrogenic Differentiation: Paraffin Embedding and Alcian Blue Staining Protocol
1. Remove the chondrogenic differentiation media from the 15 ml tube and fix the sample by
adding 500 l of 4% PFA. Store at 4°C overnight.
2. Turn on all equipment of the tissue embedding station the day before to melt the paraffin beads.
3. Label plastic cassettes with pencil and label paper strip in pencil making a circle were the
sample is going to be placed in.
4. To remove the pellet from the 15ml tube use a 1000 l pipette to aspirate it. Hold the pipette
vertically and watch the pellet go to the tip falling by gravity. Then, just touch the paper in the
drawn circle while making only a small discharge with the pipette. Avoid discarding a lot of PFA
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since it might move the pellet from the center of the drawn circle. It is advasibale to wear
goggles and to place several tissue papers under the paper strip to absorb any excess of PFA.
5. Fold the paper to make sure pellet will not come out of it and put it in a labeled cassette.
6. Place the cassettes in a beaker and start with the dehydration process.
Reagent
a. 70% Ethyl alcohol
b. 80% Ethyl alcohol
c. 95% Ethyl alcohol
d. 95% Ethyl alcohol
e. 100% Ethyl alcohol
f. 100% Ethyl alcohol
g. 100% Ethyl alcohol
h. Xylene
i. Xylene
j. Paraffin Ca 58ºC (m.p. = 56ºC)
k. Paraffin Ca 58ºC (m.p. = 56ºC)
l. Paraffin Ca 58ºC (m.p. = 56ºC)
m. Paraffin under vacuum, 58ºC

Manual time
1 hour
30 minutes
30 minutes
30 minutes
30 minutes
30 minutes
30 minutes
30 minutes
30 minutes
30 minutes
30 minutes
30 minutes
Overnight

7. Remove cassette from paraffin using hot forceps and place it on the warm plate of the tissue
embedding station.
8. Fill a metal mold with paraffin and leave it in the plate of the tissue embedding station. Make
sure that the mold is small, in order to easily track the pellet in the center of the mold for later
paraffin sections.
9. Remove the folded paper strip from cassette, place it in the warm plate of the tissue
embedding station and carefully open it using hot forceps.
10. Place the pellet inside of the paraffin-filled mold by using the tip of a scalpel blade
(previously warmed).
11. Move the mold to the cold plate of the tissue embedding station. Let it cool but not
completely harden before putting the back of the cassette on top of the mold. Fill with more
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paraffin until the whole back of the cassette is covered in paraffin and let it harden on the cold
plate for around 1 hour.
12. Once hardened, remove the cassette from the mold and cut around the edges with a razor
blade to remove excess of paraffin. Paraffin blocks can be stored at 4ºC until sections are done.
13. Make sure that the blade on the microtome is sharp. When cutting a large number of samples,
the blade may need to be changed as often as once a day. Never change the angle of the blade
once it is set. Clamp sample into the block on the microtome. Set thickness to 5-7 microns. Make
at least 5 sections to place in one slide.
14. Deparaffanize and hydrate to distillated water: Place the slides in a rack, and perform the
following washes:
a) Xylene: 2 x 3 minutes
b) 95% ethanol: 3 minutes
c) 70 % ethanol: 3 minutes
d) 50 % ethanol: 3 minutes
e) Running cold tap water to rinse (3 minutes)
15. Mordant the sections in 3% acetic acid in distilled water. Drain the slides. Do not rinse.
16. Place the slides in a solution containing 1% Alcian Blue (Acros Organic, 400460100) in 3%
acetic acid (Adjust pH to 2.5) for 30 minutes
17. Running cold tap water to rinse (2 minutes).
18. Counter stain with Nuclear Fast Red (Leica, 38016SS3B) for 3 minutes.
19. Running cold tap water to rinse (2 minutes).
20. Dehydrate by moving the slides 4 times in four different 100% ethanol solutions. Move the
slides three times in 3 different Xylene solutions. Leave the slides in the last one until mounting.
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21. Without rinsing the Xylene from the slide mount them with Permount (Fisher, SP15-500) by
placing a small drop in the center of the slide. Apply a cover slide on top. Microwave for 1
minute to seal the Permount.
Cell Proliferation Assay
In order to evaluate cell proliferation after induction of pluripotency and expansion until P10 the
alamarBlue® (Molecular Probes®, DAL1025) dye was employed. The alamarBlue® assay is
quantitative with respect to time and dose as seen by the ability of metabolically active cells to
convert the reagent into a fluorescent and colorimetric indicator. First, a standard curve was
developed to determine the time of incubation of the dye with the cells. This was necessary to
establish when the fluorescence intensity of alamarBlue® is directly proportional to a cell
number range. When a short incubation time is used, a high resolution for a large number of cells
(around 50,000 cells) is obtained. To gain more resolution for detecting the influence of a few
cells (as low as 50) a longer incubation time is needed. Based on an estimated number of cells in
one well of a 96 well plate was expected to be between 1,500-12,000 according to the seeding
density (1,000/cm2) and the duration of this assay (21 days), the time when the fluorescent
intensity and this cell number range were linear was 2 hours incubation. The measurements for
each time point were taken in three independent replicates on days 0, 7, 14 and 21 of culture.
Although the dye allowed repeated measures in the same well, to avoid the influence of not
independent measurements new wells were measured on each time point. Every well contained
100 µl of stromal media and 10 µl of the alamarBlue® dye was added. Measurements were
detected in a Bio-Tek FLx800 Synergy HT plate reader with a KC4 v2.7 software.
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APPENDIX B
Table B.1 PCR Primers

Primer
OCT4 Forward

Sequence (5'-3')
GTGAAGGTGGACAAGGAGAAG

OCT4 Reverse

CGGCAGATGGTCGTTTGG

KLF4 Forward

GTTCTCATCTCAAGGCACACC

KLF4 Reverse

TCGCACTTCTGGCACTGG

SOX2 Forward

ATGGGTTCGGTGGTCAAGTC

SOX2 Reverse

GCCGCTCTGGTAGTGCTG

TNC Forward

TAGTAACGGTGGTGGATTCTGG

TNC Reverse

CGGCTCGGCTTCTGTAACA

PAP Forward

TGTGGGTGATTGGGTTAGTG

PAP Reverse

TGATTAGGTAGTAGTTGATGGAGT

HPRT-1 Forward CGAGATGTGATGAAGGAGATG

Amplicon
Leng
ht
194

Accesion #
XM_001490108.3

157

XM_001492956.3

202

XM_003363345.1

185

XM_001916622.3

193

XM_001489078.3

233

XM_001490189.2

HPRT-1 Reverse TTTCCAGTTAAAGTTGAGAGGTC

Fig B.1 Amplicon size validation for OCT4, KLF4 and 18SrRNA (not used in further
experiments)
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Fig B.2 Amplicon size validation for KLF4 and SOX2.

Fig B.3 Amplicon size validation for TNC, PAP and HPRT-1.
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Fig B.4 Temperature gradient for the KLF4 primer tested against equine sequence

.
Fig B.5 Temperature gradient for the KLF4 primer tested against human sequence
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Fig B.6 Temperature gradient for the OCT4 primer tested against equine sequence

Fig B.7 Temperature gradient for the OCT4 primer tested against human sequence
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OCT4 Primer and Calibrator Evaluation

Fig B.8 OCT4 qRT-PCR Amplification/Cycle graph

Fig B.9 OCT4 Standard curve
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Fig B.10 OCT4 Melting curve

KLF4 Primer and Calibrator Evaluation

Fig B.11 KLF4 qRT-PCR Amplification/Cycle graph
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Fig B.12 KLF4 Standard curve

Fig B.13 KLF4 Melting curve
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SOX2 Primer and Calibrator Evaluation

Fig B.14 SOX2 qRT-PCR Amplification/Cycle graph

Fig B.15 SOX2 Standard curve
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Fig B.16 SOX2 Melting curve

PAP Primer and Calibrator Evaluation

Fig B.17 PAP qRT-PCR Amplification/Cycle graph
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Fig B.18 PAP Standard curve

Fig B.19 PAP Melting curve
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HPRT-1 Primer and Calibrator Evaluation

Fig B.20 HPRT-1 qRT-PCR Amplification/Cycle graph

Fig B.21 HPRT-1 Standard curve
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Fig B.22 HPRT-1 Melting curve

TNC Primer and Calibrator Evaluation

Fig B.23 TNC qRT-PCR Amplification/Cycle graph
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Fig B.24 TNC Standard curve

Fig B.25 TNC Melting curve
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